(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number
WO 02/34900 A1

(51) International Patent Classification[7]: C12N 9/64, 5/10, 5/12, A61K 38/43, C07K 16/40

(21) International Application Number: PCT/AU01/01388

(22) International Filing Date: 29 October 2001 (29.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PR 1078 27 October 2000 (27.10.2000) AU

(71) Applicant *(for all designated States except US)*: **THE UNIVERSITY OF SYDNEY** [AU/AU]; Parramatta Road, Sydney, New South Wales 2006 (AU).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ABBOTT, Catherine, Anne** [AU/AU]; c/- The University of Sydney, Parramatta Road, Sydney, New South Wales 2006 (AU). **GORRELL, Mark, Douglas** [AU/AU]; c/- The University of Sydney, Parramatta Road, Sydney, New South Wales 2006 (AU).

(74) Agent: **GRIFFITH HACK**; GPO Box 4164, SYDNEY, New South Wales 2001 (AU).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/34900 A1

(54) Title: DIPEPTIDYL PEPTIDASES

(57) Abstract: Peptides which comprise sequences as shown in Seq ID NO:2 or HisGlyTrpSerTypGlyGlyPheLeu; LeuAspGluAsnValHisPhePhe; GluArgHisSerIleArg and PheValIleGlnGluGluPhe which show peptidase ability and have substrate specificity for at least one of the compounds H-Ala-Pro-pNA, H-Gly-Pro-pNA, H-Gly-Pro-pNA ans H-Arg-Pro-pNA. peptides having sequence ID No:7 are also claimed. Nucleic acids, vectors, antibodies and hybridoma cells are also claimed with reference to the above sequences and there abilities.

TITLE

DIPEPTIDYL PEPTIDASES

FIELD OF INVENTION

The invention relates to a dipeptidyl peptidase, to a nucleic acid molecule which encodes it, and to uses of the peptidase.

BACKGROUND OF THE INVENTION

The dipeptidyl peptidase (DPP) IV-like gene family is a family of molecules which have related protein structure and function [1-3]. The gene family includes the following molecules: DPPIV (CD26), dipeptidyl amino-peptidase-like protein 6 (DPP6), dipeptidyl amino-peptidase-like protein 8 (DPP8) and fibroblast activation protein (FAP) [1,2,4,5]. Another possible member is DPPIV-β[6].

The molecules of the DPPIV-like gene family are serine proteases, they are members of the peptidase family S9b, and together with prolyl endopeptidase (S9a) and acylaminoacyl peptidase (S9c), they are comprised in the prolyl oligopeptidase family[5,7].

DPPIV and FAP both have similar postproline dipeptidyl amino peptidase activity, however, unlike DPPIV, FAP also has gelatinase activity[8,9].

DPPIV substrates include chemokines such as RANTES, eotaxin, macrophage-derived chemokine and stromal-cell-derived factor 1; growth factors such as glucagon and glucagon-like peptides 1 and 2; neuropeptides including neuropeptide Y and substance P; and vasoactive peptides[10-12].

DPPIV and FAP also have non-catalytic activity; DPPIV binds adenosine deaminase, and FAP binds to $\alpha_3\beta_1$ and $\alpha_5\beta_1$ integrin[13-14].

In view of the above activities, the DPPIV-like family members are likely to have roles in intestinal and renal handling of proline containing peptides, cell adhesion, peptide metabolism, including metabolism of cytokines, neuropeptides, growth factors and chemokines, and immunological processes, specifically T cell stimulation[3,11,12].

Consequently, the DPPIV-like family members are likely to be involved in the pathology of disease, including for example, tumour growth and biology, type II diabetes, cirrhosis, autoimmunity, graft rejection and HIV infection[3,15-18].

Inhibitors of DPPIV have been shown to suppress arthritis, and to prolong cardiac allograft survival in animal models *in vivo*[19,20]. Some DPPIV inhibitors are reported to inhibit HIV infection[21]. It is anticipated that DPPIV inhibitors will be useful in other therapeutic applications including treating diarrhoea, growth hormone deficiency, lowering glucose levels in non insulin dependent diabetes mellitus and other disorders involving glucose intolerance, enhancing mucosal regeneration and as immunosuppressants[3,21-24].

There is a need to identify members of the DPPIV-like gene family as this will allow the identification of inhibitor(s) with specificity for particular family member(s), which can then be administered for the purpose of treatment of disease. Alternatively, the identified member may of itself be useful for the treatment of disease.

SUMMARY OF THE INVENTION

The present invention seeks to address the above identified need and in a first aspect provides a peptide which comprises the amino acid sequence shown in SEQ ID NO:2.

As described herein, the inventors believe that the peptide is a prolyl oligopeptidase and a dipeptidyl peptidase, because it has substantial and significant homology with the amino acid sequences of DPPIV and DPP8. As homology is observed between DPP8, DPPIV and DPP9, it will be understood that DPP9 has a substrate specificity for at least one of the following compounds: H-Ala-Pro-pNA, H-Gly-Pro-pNA and H-Arg-Pro-pNA.

The peptide is homologous with human DPPIV and DPP8, and importantly, identity between the sequences of DPPIV and DPP8 and SEQ ID NO: 2 is observed at the regions of DPPIV and DPP8 containing the catalytic triad residues and the two glutamate residues of the β-propeller domain essential for DPPIV enzyme activity. The observation of amino acid sequence homology means that the peptide which has the amino acid sequence shown in SEQ ID NO:2 is a member of the DPPIV-like gene family. Accordingly the peptide is now named and described herein as DPP9.

The following sequences of the human DPPIV amino acid sequence are important for the catalytic activity of DPPIV: (i) Trp^{617}GlyTrpSerTyrGlyGlyTyrVal; (ii) Ala^{707}AspAspAsnValHisPhe; (iii) Glu^{738}AspHisGlyIleAlaSer; and (iv) Trp^{201}ValTyrGluGluGluVal [25-28]. As described herein, the alignment of the following sequences of DPP9: His^{833}GlyTrpSerTyrGlyGlyPheLeu; Leu^{913}AspGluAsnValHisPhePhe; Glu^{944}ArgHisSerIleArg and Phe^{350}ValIleGlnGluGluPhe with sequences (i) to (iv) above, respectively, suggests that these sequences of DPP9 are likely to confer the catalytic activity of DPP9. This is also supported by the alignment of DPP9 and DPP8 amino acid sequences. More specifically, DPP8 has substrate specificity for H-Ala-Pro-pNA, H-Gly-Pro-pNA and H-Arg-Pro-pNA, and shares near identity, with only one position of amino acid difference, in each of the above described sequences of DPP9. Thus, in a second aspect, the invention provides a peptide comprising the following amino acid sequences:

HisGlyTrpSerTyrGlyGlyPheLeu; LeuAspGluAsnValHisPhePhe; GluArgHisSerIleArg and PheValIleGlnGluGluPhe; which has the substrate specificity of the sequence shown in SEQ ID NO:2.

Also described herein, using the GAP sequence alignment algorithm, it is observed that DPP9 has 53% amino acid similarity and 29% amino acid identity with a *C. elegans* protein. Further, as shown herein, a nucleic acid molecule which encodes DPP9, is capable of hybridising specifically with DPP9 sequences derived from non-human species, including rat and mouse. Further, the inventors have isolated and characterised a mouse homologue of human DPP9. Together these data demonstrate that DPP9 is expressed in non-human species. Thus in a third aspect, the invention provides a peptide which has at least 91% amino acid identity with the amino acid sequence shown in SEQ ID NO:2, and which has the substrate specificity of the sequence shown in SEQ ID NO:2. Typically the peptide has the sequence shown in SEQ ID NO:4. Preferably, the amino acid identity is 75%. More preferably, the amino acid identity is 95%. Amino acid identity is calculated using GAP software [GCG Version 8, Genetics Computer Group, Madison, WI, USA] as described further herein. Typically, the peptide comprises the following sequences: HisGlyTrpSerTyrGlyGlyPheLeu; LeuAspGluAsnValHisPhePhe; GluArgHisSerIleArg and PheValIleGlnGluGluPhe.

In view of the homology between DPPIV, DPP8 and DPP9 amino acid sequences, it is expected that these sequences will have similar tertiary structure. This means that the tertiary structure of DPP9 is likely to include the seven-blade β- propeller domain and the α/β hydrolase domain of DPPIV. These structures in DPP9 are likely to be conferred by the regions comprising β-propeller, Val^{226} to Ala^{705}, α/β hydrolase, Ser^{706} to Leu^{969} and about 70 to 90 residues in the region Ser^{136} to Gly^{225}. As it is known that the β-propeller domain regulates proteolysis mediated by the catalytic triad in the α/β hydrolase domain of prolyl

oligopeptidase, [29] it is expected that truncated forms of DPP9 can be produced, which have the substrate specificity of the sequence shown in SEQ ID NO:2, comprising the regions referred to above ($His^{833}GlyTrpSerTyrGlyGlyPheLeu$; $Leu^{913}AspGluAsnValHisPhePhe$; $Glu^{944}ArgHisSerIleArg$ and $Phe^{350}ValIleGlnGluGluPhe$) which confer the catalytic specificity of DPP9. Examples of truncated forms of DPP9 which might be prepared are those in which the region conferring the β-propeller domain and the α/β hydrolase domain are spliced together. Other examples of truncated forms include those that are encoded by splice variants of DPP9 mRNA. Thus although, as described herein, the biochemical characterisation of DPP9 shows that DPP9 consists of 969 amino acids and has a molecular weight of about 110 kDa, it is recognised that truncated forms of DPP9 which have the substrate specificity of the sequence shown in SEQ ID NO:2, may be prepared using standard techniques [30,31]. Thus in a fourth aspect, the invention provides a fragment of the sequence shown in SEQ ID NO: 2, which has the substrate specificity of the sequence shown in SEQ ID NO:2. The inventors believe that a fragment from Ser136 to Leu969 (numbered according to SEQ ID NO:2) would have enzyme activity.

It is recognised that DPP9 may be fused, or in other words, linked to a further amino acid sequence, to form a fusion protein which has the substrate specificity of the sequence shown in SEQ ID NO:2. An example of a fusion protein is one which comprises the sequence shown in SEQ ID NO:2 which is linked to a further amino acid sequence: a "tag" sequence which consists of an amino acid sequence encoding the V5 epitope and a His tag. An example of another further amino acid sequence which may be linked with DPP9 is a glutathione S transferase (GST) domain [30]. Another example of a further amino acid sequence is a portion of CD8α [8]. Thus in one aspect, the invention provides a fusion protein comprising the amino acid sequence shown in

SEQ ID NO:2 linked with a further amino acid sequence, the fusion protein having the substrate specificity of the sequence shown in SEQ ID NO:2.

It is also recognised that the peptide of the first aspect of the invention may be comprised in a polypeptide, so that the polypeptide has the substrate specificity of DPP9. The polypeptide may be useful, for example, for altering the protease susceptibility of DPP9, when used in *in vivo* applications. An example of a polypeptide which may be useful in this regard, is albumin. Thus in another embodiment, the peptide of the first aspect is comprised in a polypeptide which has the substrate specificity of DPP9.

In one aspect, the invention provides a peptide which includes the amino acid sequence shown in SEQ ID NO:7. In one embodiment the peptide consists of the amino acid sequence shown in SEQ ID NO:7.

As described further herein, the amino acid sequence shown in SEQ ID NO:7, and the amino acid sequences of DPPIV, DPP8 and FAP are homologous. DPPIV, DPP8 and FAP have dipeptidyl peptidase enzymatic activity and have substrate specificity for peptides which contain the di-peptide sequence, Ala-Pro. The inventors note that the amino acid sequence shown in SEQ ID NO:7 contains the catalytic triad, Ser-Asp-His. Accordingly, it is anticipated that the amino acid sequence shown in SEQ ID NO:7 has enzymatic activity in being capable of cleaving a peptide which contains Ala-Pro by hydrolysis of a peptide bond located C-terminal adjacent to proline in the di-peptide sequence.

In one embodiment, the peptide comprises an amino acid sequence shown in SEQ ID NO:7 which is capable of cleaving a peptide bond which is C-terminal adjacent to proline in the sequence Ala-Pro. The capacity of a dipeptidyl

peptidase to cleave a peptide bond which is C-terminal adjacent to proline in the di-peptide sequence Ala-Pro can be determined by standard techniques, for example, by observing hydrolysis of a peptide bond which is C-terminal adjacent to proline in the molecule Ala-Pro-p-nitroanilide.

The inventors recognise that by using standard techniques it is possible to generate a peptide which is a truncated form of the sequence shown in SEQ ID NO:7, which retains the proposed enzymatic activity described above. An example of a truncated form of the amino acid sequence shown in SEQ ID NO:7 which retains the proposed enzymatic activity is a form which includes the catalytic triad, Ser-Asp-His. Thus a truncated form may consist of less than the 831 amino acids shown in SEQ ID NO:7. Accordingly, in a further embodiment, the peptide is a truncated form of the peptide shown in SEQ ID NO:7, which is capable of cleaving a peptide bond which is C-terminal adjacent to proline in the sequence Ala-Pro.

It will be understood that the amino acid sequence shown in SEQ ID NO:7 may be altered by one or more amino acid deletions, substitutions or insertions of that amino acid sequence and yet retain the proposed enzymatic activity described above. It is expected that a peptide which is at least 47% similar to the amino acid sequence of SEQ ID NO:7, or which is at least 27% identical to the amino acid sequence of SEQ ID NO:7, will retain the proposed enzymatic activity described above. The % similarity can be determined by use of the program/algorithm "GAP" which is available from Genetics Computer Group(GCG),Wisconsin. Thus in another embodiment of the first aspect, the peptide has an amino acid sequence which is at least 47% similar to the amino acid sequence shown in SEQ ID NO:7, and is capable of cleaving a peptide bond which is C-terminal adjacent to proline in the sequence Ala-Pro.

As described above, the isolation and characterisation of DPP9 is necessary for identifying inhibitors of DPP9 catalytic activity, which may be useful for the treatment of disease. Accordingly, in a fifth aspect, the invention provides a method of identifying a molecule capable of inhibiting cleavage of a substrate by DPP9, the method comprising the following steps:

(a) contacting DPP9 with the molecule;

(b) contacting DPP9 of step (a) with a substrate capable of being cleaved by DPP9, in conditions sufficient for cleavage of the substrate by DPP9; and

(c) detecting substrate not cleaved by DPP9, to identify that the molecule is capable of inhibiting cleavage of the substrate by DPP9.

It is recognised that although inhibitors of DPP9 may also inhibit DPPIV and other serine proteases, as described herein, the alignment of the DPP9 amino acid sequence with most closely related molecules, (i.e. DPPIV), reveals that the DPP9 amino acid is distinctive, particularly at the regions controlling substrate specificity. Accordingly, it is expected that it will be possible to identify inhibitors which inhibit DPP9 catalytic activity specifically, which do not inhibit catalytic activity of DPPIV-like gene family members, or other serine proteases. Thus, in a sixth aspect, the invention provides a method of identifying a molecule capable of inhibiting specifically, the cleavage of a substrate by DPP9, the method comprising the following steps:

(a) contacting DPP9 and a further protease with the molecule;

(b) contacting DPP9 and the further protease of step (a) with a substrate capable of being cleaved by DPP9 and the further protease, in conditions sufficient for cleavage of the substrate by DPP9 and the further protease; and

(c) detecting substrate not cleaved by DPP9, but cleaved by the further protease, to identify that the molecule is capable of inhibiting specifically, the cleavage of the substrate by DPP9.

In a seventh aspect, the invention provides a method of reducing or inhibiting the catalytic activity of DPP9, the method comprising the step of contacting DPP9 with an inhibitor of DPP9 catalytic activity. In view of the homology between DPP9 and DPP8 amino acid sequences, it will be understood that inhibitors of DPP8 activity may be useful for inhibiting DPP9 catalytic activity. Examples of inhibitors suitable for use in the seventh aspect are described in [21,32,33]. Other inhibitors useful for inhibiting DPP9 catalytic activity can be identified by the methods of the fifth or sixth aspects of the invention.

In one embodiment, the catalytic activity of DPP9 is reduced or inhibited in a mammal by administering the inhibitor of DPP9 catalytic activity to the mammal. It is recognised that these inhibitors have been used to reduce or inhibit DPPIV catalytic activity *in vivo*, and therefore, may also be used for inhibiting DPP9 catalytic activity *in vivo*. Examples of inhibitors useful for this purpose are disclosed in the following [21,32-34].

Preferably, the catalytic activity of DPP9 in a mammal is reduced or inhibited in the mammal, for the purpose of treating a disease in the mammal. Diseases which are likely to be treated by an inhibitor of DPP9 catalytic activity are those in which DPPIV-like gene family members are associated [3,10,11,17,21,36], including for example, neoplasia, type II diabetes, cirrhosis, autoimmunity, graft rejection and HIV infection.

Preferably, the inhibitor for use in the seventh aspect of the invention is one which inhibits the cleavage of a peptide bond C-terminal adjacent to proline. As described

herein, examples of these inhibitors are 4-(2-aminoethyl)benzenesulfonylfluoride, aprotinin, benzamidine/HCl, Ala-Pro-Gly, H-Lys-Pro-OH HCl salt and zinc ions, for example, zinc sulfate or zinc chloride. More preferably, the inhibitor is one which specifically inhibits DPP9 catalytic activity, and which does not inhibit the catalytic activity of other serine proteases, including, for example DPPIV, DPP8 or FAP.

In an eighth aspect, the invention provides a method of cleaving a substrate which comprises contacting the substrate with DPP9 in conditions sufficient for cleavage of the substrate by DPP9, to cleave the substrate. Examples of molecules which can be cleaved by the method are H-Ala-Pro-pNA, H-Gly-Pro-pNA and H-Arg-Pro-pNA. Molecules which are cleaved by DPPIV including RANTES, eotaxin, macrophage-derived chemokine, stromal-cell-derived factor 1, glucagon and glucagon-like peptides 1 and 2, neuropeptide Y, substance P and vasoactive peptide are also likely to be cleaved by DPP9 [11,12]. In one embodiment, the substrate is cleaved by cleaving a peptide bond C-terminal adjacent to proline in the substrate. The molecules cleaved by DPP9 may have Ala, or Trp, Ser, Gly, Val or Leu in the P1 position, in place of Pro [11,12].

The inventors have characterised the sequence of a nucleic acid molecule which encodes the amino acid sequence shown in SEQ ID NO:2. Thus in a tenth aspect, the invention provides a nucleic acid molecule which encodes the amino acid sequence shown in SEQ ID NO:2.

In an eleventh aspect, the invention provides a nucleic acid molecule which consists of the sequence shown in SEQ ID NO:1.

In another aspect, the invention provides a nucleic acid molecule which encodes a peptide comprising the amino acid sequence shown in SEQ ID NO:7.

The inventors have characterised the nucleotide sequence of the nucleic acid molecule encoding SEQ ID NO:7. The nucleotide sequence of the nucleic acid molecule encoding DPP4-like-2 is shown in SEQ ID NO:8. Thus, in one embodiment, the nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO:8. In another embodiment, the nucleic acid molecule consists of the nucleotide sequence shown in SEQ ID NO:8.

The inventors recognise that a nucleic acid molecule which has the nucleotide sequence shown in SEQ ID NO:8 could be made by producing only the fragment of the nucleotide sequence which is translated. Thus in an embodiment, the nucleic acid molecule does not contain 5' or 3' untranslated nucleotide sequences.

As described herein, the inventors observed RNA of 4.4 kb and a minor band of 4.8 kb in length which hybridised to a nucleic acid molecule comprising sequence shown in SEQ ID NO:8. It is possible that these mRNA species are splice variants. Thus in another embodiment, the nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO:8 and which is approximately 4.4 kb or 4.8 kb in length.

In another embodiment, the nucleic acid molecule is selected from the group of nucleic acid molecules consisting of DPP4-like-2a, DPP4-like-2b and DPP4-like-2c, as shown in Figure 2.

In another aspect, the invention provides a nucleic acid molecule having a sequence shown in SEQ ID NO: 3.

In a twelfth aspect, the invention provides a nucleic acid molecule which is capable of hybridising to a nucleic acid molecule consisting of the sequence shown in SEQ ID NO:1 in stringent conditions, and which encodes a peptide which has the substrate specificity of the sequence shown in SEQ ID NO:2. As shown in the Northern blot analysis described herein, DPP9 mRNA hybridises specifically to the sequence shown in SEQ ID NO:1, after washing in 2XSSC/ 1.0%SDS at 37°C, or after washing in 0.1XSSC/0.1% SDS at 50°C. "Stringent conditions" are conditions in which the nucleic acid molecule is exposed to 2XSSC/ 1.0% SDS. Preferably, the nucleic acid molecule is capable of hybridising to a molecule consisting of the sequence shown in SEQ ID NO:1 in high stringent conditions. "High stringent conditions" are conditions in which the nucleic acid molecule is exposed to 0.1XSSC/ 0.1%SDS at 50°C.

As described herein, the inventors believe that the gene which encodes DPP9 is located at band p13.3 on human chromosome 19. The location of the DPP9 gene is distinguished from genes encoding other prolyl oligopeptidases, which are located on chromosome 2, at bands 2q24.3 and 2q23, chromosome 7 or chromosome 15q22. Thus in an embodiment, the nucleic acid molecule is one capable of hybridising to a gene which is located at band p13.3 on human chromosome 19.

It is recognised that a nucleic acid molecule which encodes the amino acid sequence shown in SEQ ID NO:2, or which comprises the sequence shown in SEQ ID NO:1, could be made by producing the fragment of the sequence which is translated, using standard techniques [30,31]. Thus in an embodiment, the nucleic acid molecule does not contain 5' or 3' untranslated sequences.

In a thirteenth aspect, the invention provides a vector which comprises a nucleic acid molecule of the tenth aspect of the invention. In one embodiment, the vector is capable of replication in a COS-7 cell, CHO cell or 293T cell, or E.coli. In another embodiment, the vector is selected from the group consisting of λTripleEx, pTripleEx, pGEM-T Easy Vector, pSecTag2Hygro, pet15b, pEE14.HCMV.gs and pCDNA3.1/V5/His.

In a fourteenth aspect, the invention provides a cell which comprises a vector of the thirteenth aspect of the invention. In one embodiment, the cell is an E.coli cell. Preferably, the E. coli is MC1061, DH5α, JM109, BL21DE3, pLysS. In another embodiment, the cell is a COS-7, COS-1, 293T or CHO cell.

In a fifteenth aspect, the invention provides a method for making a peptide of the first aspect of the invention comprising, maintaining a cell according to the fourteenth aspect of the invention in conditions sufficient for expression of the peptide by the cell. The conditions sufficient for expression are described herein. In one embodiment, the method comprises the further step of isolating the peptide.

In a sixteenth aspect, the invention provides a peptide when produced by the method of the fifteenth aspect.

In a seventeenth aspect, the invention provides a composition comprising a peptide of the first aspect and a pharmaceutically acceptable carrier.

In an eighteenth aspect, the invention provides an antibody which is capable of binding a peptide according to the first aspect of the invention. The antibody can be

prepared by immunising a subject with purified DPP9 or a fragment thereof according to standard techniques [35]. An antibody may be prepared by immunising with transiently transfected DPP9$^+$ cells. It is recognised that the antibody is useful for inhibiting activity of DPP9. In one embodiment, the antibody of the eighteenth aspect of the invention is produced by a hybridoma cell.

In a nineteenth aspect, the invention provides a hybridoma cell which secretes an antibody of the nineteenth aspect.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1. Nucleotide sequence of DPP8 (SEQ ID NO:5).

Figure 2. Schematic representation of the cloning of human cDNA DPP9.

Figure 3. Schematic representation of the assembly of nucleotide sequences of human cDNA DPP9.

Figure 4. Nucleotide sequence of human cDNA DPP9 (SEQ ID NO:1) and amino acid sequence of human DPP9 (SEQ ID NO:2).

Figure 5. Alignment of human DPP9 amino acid sequences with the amino acid sequence encoded by a predicted open reading frame of GDD.

Figure 6. Alignment of human DPP8, DPP9, DPP4 and FAP amino acid sequences.

Figure 7. Northern blot analysis of human DPP9 RNA.

Figure 8. Alignment of murine (SEQ ID NO:4) and human DPP9 amino acid sequences.

Figure 9. Alignment of murine (SEQ ID NO:3) and human DPP9 cDNA nucleotide sequences.

Figure 10. Northern blot analysis of rat DPP9 RNA.

Figure 11. Detection of DPP9 cDNA in CEM cells.

Figure 12. Detection of murine DPP9 nucleotide sequence.

DETAILED DESCRIPTION OF THE INVENTION

EXAMPLES

General

Restriction enzymes and other enzymes used in cloning were obtained from Boehringer Mannheim Roche. Standard molecular biology techniques were used unless indicated otherwise.

DPP9 Cloning

The nucleotide sequence of DPP8 shown in Figure 1 was used to search the GenBank database for homologous nucleotide sequences. Nucleotide sequences referenced by GenBank accession numbers AC005594 and AC005783 were detected and named GDD. The GDD nucleotide sequence is 39.5 kb and has 19 predicted exons. The analysis of the predicted exon-intron boundaries in GDD suggests that the predicted open reading frame of GDD is 3.6 kb in length.

In view of the homology of DPP8 and the GDD nucleotide sequences, we hypothesised the existence of DPPIV-like molecules other than DPP8. We used oligonucleotide primers derived from the nucleotide sequence of GDD and reverse transcription PCR (RT-PCR) to isolate a cDNA encoding DPPIV-like molecules.

RT-PCR amplification of human liver RNA derived from a pool of 4 patients with autoimmune hepatitis using the primers GDD pr 1F and GDD pr 1R (Table 1) produced a 500 base pair product. This suggested that DPPIV-like molecules are likely to be expressed in liver cells derived from individuals with autoimmune hepatitis and that RNA derived from these cells is likely to be a suitable source for isolating cDNA clones encoding DPPIV-like molecules.

Primers GDD pr 3F and GDD pr 1R (Table 1) were then used to isolate a cDNA clone encoding a DPP4-like molecule. A 1.6 kb fragment was observed named DPP4-like-2a. Primers GDD

pr 15F and GDD pr 7R (Table 1) were then used to isolate a cDNA clone encoding a DPP4-like molecule. A 1.9 kb product was observed and named DPP4-like-2b. As described further herein, the sequence of DPP4-like-2b overlaps with the sequence of DPP4-like-2a.

The DPP4-like-2a and 2b fragments were gel purified using WIZARD® PCR preps kit and cloned into the pGEM®-T-easy plasmid vector using the *Eco*RI restriction sites. The ligation reaction was used to transform JM109 competent cells. The plasmid DNA was prepared by miniprep. The inserts were released by *Eco*RI restriction digestion. The DNA was sequenced in both directions using the M13Forward and M13Reverse sequencing primers. The complete sequence of DPP4-like-2a and 2b fragments was derived by primer walking.

The nucleotide sequence 5' adjacent to DPP4-like-2b was obtained by 5'RACE using dC tailing and the gene specific primers GDD GSP1.1 and 2.1 (Table 1). A fragment of 500 base pairs (DPP4-like-2c) was observed. The fragment was gel purified using WIZARD® PCR preps kit and cloned into the pGEM®-T-easy plasmid vector using the *Eco*RI restriction sites. The ligation reaction was used to transform JM109 competent cells. The plasmid DNA was prepared by miniprep. The inserts were released by *Eco*RI restriction digestion. The DNA was sequenced in both directions using the M13Forward and M13Reverse sequencing primers.

We identified further sequences, BE727051 and BE244612, with identity to the 5' end of DPP9. These were discovered while performing BLASTn with the 5' end of the DPP9 nucleotide sequence. BE727051 contained further 5' sequence for DPP9, which was also present in the genomic sequence for DPP9 on chromosome 19p13.3. This was used to design primer DPP9-22F (5'GCCGGCGGGTCCCCTGTGTCCG3'). Primer 22F

was used in conjunction with primer GDD3'end (5'GGGCGGGACAAAGTGC CTCACTGG3') on cDNA made from the human CEM cell line to produce a 3000bp product as expected Figure 11.

Nucleotide sequence analysis of DPP4-like-2a, 2b, and 2c fragments.

An analysis of the nucleotide sequence of fragments DPP4-like 2a, 2b and 2c with the Sequencher™ version 3.0 computer program (Figure 3), and the 5' fragment isolated by primers DPP9-22F and GDD3'end, revealed the nucleotide sequence shown in Figure 4.

The predicted amino acid sequence shown in Figure 4 was compared to a predicted amino acid sequence encoded by a predicted open reading frame of GDD (predicted from the nucleotide sequence referenced by GenBank Accession Nos. AC005594 and AC005783), to determine the relatedness of the nucleotide sequence of Figure 4 to the nucleotide sequence of the predicted open reading frame of GDD (Figure 5). Regions of amino acid identity were observed suggesting that there may be regions of nucleotide sequence identity of the predicted open reading frame of GDD and the sequence of Figure 4. However, as noted in Figure 5, there are regions of amino acid sequence encoded by the sequence of Figure 4 and the amino acid sequence encoded by the predicted open reading frame of GDD which are not identical, demonstrating that the nucleotide sequences encoding the predicted open reading frame of GDD and the sequence shown in Figure 4 are different nucleotide sequences.

As described further herein, the predicted amino acid sequence encoded by the cDNA sequence shown in Figure 4 is homologous to the amino acid sequence of DPP8 (Figure 6). Accordingly, and as a cDNA consisting of the nucleotide

sequence shown in Figure 4 was not known, the sequence shown in Figure 4 was named cDNA DPP9.

The predicted amino acid sequence encoded by cDNA DPP9 (called DPP9) is 969 amino acids and is shown in Figure 4. The alignment of DPP9 and DPP8 amino acid sequences suggests that the nucleotide sequence shown in Figure 4 may be a partial length clone. Notwithstanding this point, as discussed below, the inventors have found that the alignment of DPP9 amino acid sequence with the amino acid sequences of DPP8, DPP4 and FAP shows that DPP9 comprises sequence necessary for providing enzymolysis and utility. In view of the similarity between DPP9 and DPP8, a full length clone may be of the order of 882 amino acids. A full length clone could be obtained by standard techniques, including for example, the RACE technique using an oligonucleotide primer derived from the 5' end of cDNA DPP9.

In view of the homology between the DPP8 and DPP9 amino acid sequences, it is likely that cDNA DPP9 encodes an amino acid sequence which has dipeptidyl peptidase enzymatic activity. Specifically, it is noted that the DPP9 amino acid sequence contains the catalytic triad Ser-Asp-His in the order of a non-classical serine protease as required for the charge relay system. The serine recognition site characteristic of DPP4 and DPP4-like family members, GYSWGG, surrounds the serine residue also suggesting that DPP9 cDNA will encode a DPP4-like enzyme activity.

Further, DPP9 amino acid sequence also contains the two glutamic acid residues located at positions 205 and 206 in DPPIV. These are believed to be essential for the dipeptidyl peptidase enzymatic activity. By sequence alignment with DPPIV, the residues in DPP8 predicted to

play a pivotal role in the pore opening mechanism in Blade 2 of the propeller are E^{259}, E^{260}. These are equivalent to the residues Glu^{205} and Glu^{206} in DPPIV which previously have been shown to be essential for DPPIV enzyme activity. A point mutation Glu259Lys was made in DPP8 cDNA using the Quick Change Site directed Mutagenesis Kit(Stratagene, La Jolla). COS-7 cells transfected with wildtype DPP8 cDNA stained positive for H-Ala-Pro4MbNA enzyme activity while the mutant cDNA gave no staining. Expression of DPP8 protein was demonstrated in COS cells transfected with wildtype and mutant cDNAs by immunostaining with anti-V5 mAB. This mAB detects the V5 epitope that has been tagged to the C-terminus of DPP8 protein. Point mutations were made to each of the catalytic residues of DPP8, Ser739A, Asp817Ala and His849Ala, and each of these residues were also determined to be essential for DPP8 enzyme activity. In summary, the residues that have been shown experimentally to be required for enzyme activity in DPPIV and DPP8 are present in the DPP9 amino acid sequence: Glu^{354}, Glu^{355}, Ser^{836}, Asp^{914} and His^{946}.

The DPP9 amino acid sequence shows the closest relatedness to DPP8, having 77% amino acid similarity and 60% amino acid identity. The relatedness to DPPIV is 25% amino acid identity and 47% amino acid similarity. The % similarity was determined by use of the program/algorithm "GAP" which is available from Genetics Computer Group(GCG),Wisconsin.

DPP9 mRNA Expression Studies

DPP4-like-2a was used to probe a Human Master RNA Blot™ (CLONTECH Laboratories Inc., USA) to study DPP9 tissue expression and the relative levels of DPP9 mRNA expression.

The DPP4-like-2a fragment hybridised to all tissue mRNA samples on the blot. The hybridisation also indicated high

levels of DPP9 expression in most of the tissues samples on the blot (data not shown).

The DPP4-like-2a fragment was then used to probe two Multiple Tissue Northern Blots™ (CLONTECH Laboratories Inc., USA) to examine the mRNA expression and to determine the size of DPP9 mRNA transcript.

The autoradiographs of the DPP9 Multiple Tissue Northern blot are shown in Figure 8. The DPP9 transcript was seen in all tissues examined confirming the results obtained from the Master RNA blot. A single major transcript 4.4 kb in size was seen in all tissues represented on two Blots after 16 hours of exposure. Weak bands could also be seen in some tissues after 6 hours of exposure. The DPP9 transcript was smaller than the 5.1 kb mRNA transcript of DPP8. A minor, very weak transcript 4.8 kb in size was also seen in the spleen, pancreas, peripheral blood leukocytes and heart. The highest mRNA expression was observed in the spleen and heart. Of all tissues examined the thymus had the least DPP9 mRNA expression. The Multiple Tissue Northern Blots were also probed with a β -actin positive control. A 2.0 kb band was seen in all tissues. In addition as expected a 1.8 kb β-actin band was seen in heart and skeletal muscle.

Rat DPP9 expression

A Rat Multiple Tissue Northern Blot (CLONTECH Laboratories, Inc., USA;catalogue #: 7764-1) was hybridised with a human DPP9 radioactively labeled probe, made using Megaprime DNA Labeling kit and [32P] dCTP (Amersham International plc, Amersham, UK). The DPP9 PCR product used to make the probe was generated using Met3F (GGCTGAGAG GAT GGCCACCAC CGGG) as the forward primer and GDD 3'end (GGGCGGGACAAAGTGC CTCACTGG) as the reverse primer. The hybridisation was

carried out according to the manufacturers' instructions at 60° C to detect cross-species hybridisation. After overnight hybridization the blot was washed at room temperature (2x SSC, 0.1% SDS) then at 40° C (0.1xSSC, 0.1%SDS).

The human cDNA probe identified two bands in all tissues examined except in testes. A major transcript of 4 kb in size was seen in all tissues except testes. This 4 kb transcript was strongly expressed in the liver, heart and brain. A second weaker transcript 5.5 kb in size was present in all tissues except skeletal muscle and testes. However in the brain the 5.5kb transcript was expressed at a higher level than the 4.4 kb transcript. In the testes only one transcript approximately 3.5 kb in size was detected. Thus, rat DPP9 mRNA hybridised with a human DPP9 probe indicating significant homology between DPP9 of the two species. The larger 5.5 kbtranscript observed may be due to crosshybridisation to rat DPP8.

Mouse DPP9 expression

A Unigene cluster for Mouse DPP9 was identified (UniGene Cluster Mm.33185) by homology to human DPP9. An analysis of expressed sequence tags contained in this cluster and mouse genomic sequence (AC026385) for Chromosome 17 with the Sequencher™ version 3.0 computer program revealed the nucleotide sequence shown in Figure 9. This 3517bp cDNA encodes a 869 aa mouse DPP9 protein (missing N-terminus) with 91% amino acid identity and 94 % amino acid similarity to human DPP9. The mouse DPP9 amino acid sequence also has the residues required for enzyme activity, Ser, Asp and His and the two Glu residues.

The primers mgdd-pr1F (5'ACCTGGGAGGAAGCACCCCACTGTG3') and mgdd-pr4R (5'TTCCACCTGGTCCTCAATCTCC3') were designed from

this sequence and used to amplify a 452 bp product as expected from liver mouse cDNA, as described below.

RNA preparation

B57Bl6 mice underwent carbon tetrachloride treatment to induce liver fibrosis. Liver RNA were prepared from snap-frozen tissues using the TRIzol® Reagent and other standard methods.

cDNA synthesis

2µg of liver RNA was reverse-transcribed using SuperScript II RNase H- Reverse Transcriptase (Gibco BRL).

PCR

PCR using mDPP9- 1F (ACCTGGGAGGAAGCACCCCACTGTG) as the forward primer and mDPP9-2R (CTCTCCACATGCAGGGCTACAGAC) as the reverse primer was used to synthesise a 550 base pair mouse DPP9 fragment. The PCR products were generated using AmpliTaq Gold® DNA Polymerase. The PCR was performed as follows: denaturation at 95° C for 10 min, followed by 35 cycles of denaturation at 95 ° C for 30 seconds, primer annealing at 60 ° C for 30 seconds, and an extension 72° C for 1 min.

Southern Blot

DPP9 PCR products from six mice as well as the largest human DPP9 PCR product were run on a 1% agarose gel. The DNA on the gel was then denatured using 0.4 M NaOH and transferred onto a Hybond-N+ membrane (Amersham International plc, Amersham, UK). The largest human DPP9 PCR product was radiolabeled using the Megaprime DNA Labeling kit and [32^P] dCTP (Amersham International plc, Amersham, UK). Unincorporated label was removed using a NAP column (Pharmacia Biotech, Sweden) and the denatured probe was incubated with the membrane for 2 hours at 60° C in Express Hybridisation solution (CLONTECH Laboratories, Inc., USA). (Figure 12). Thus, DPP9 mRNA of appropriate size was detected in fibrotic mouse liver using rt-PCR. Furthermore, the single band of mouse DPP9 cDNA hybridised

with a human DPP9 probe indicating significant homology between DPP9 of the two species.

REFERENCES

1. Abbott CA, GW McCaughan & MD Gorrell 1999 Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity *FEBS Letters* **458**: 278-84.

2. Abbott CA, DMT Yu, GW McCaughan & MD Gorrell 2000 Post proline peptidases having DP IV like enzyme activity *Advances in Experimental Medicine and Biology* **477**: 103-9.

3. McCaughan GW, MD Gorrell, GA Bishop, CA Abbott, NA Shackel, PH McGuinness, MT Levy, AF Sharland, DG Bowen, D Yu, L Slaitini, WB Church & J Napoli 2000 Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance *Immunological Reviews* **174**: 172-91.

4. Scanlan MJ, BK Raj, B Calvo, P Garin-Chesa, MP Sanz-Moncasi, JH Healey, LJ Old & WJ Rettig 1994 Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers *Proceedings of the National Academy of Sciences United States of America* **91**: 5657-61.

5. Handbook of Proteolytic Enzymes. Barrett AJ, ND Rawlings & JF Woess. 1998., London: Academic Press. 1666.

6. Jacotot E, C Callebaut, J Blanco, B Krust, K Neubert, A Barth & AG Hovanessian 1996 Dipeptidyl-peptidase IV-beta, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity *European Journal of Biochemistry* **239**: 248-58.

7. Rawlings ND & AJ Barrett 1999 MEROPS: the peptidase database *Nucleic Acids Research* **27**: 325-31.

8. Park JE, MC Lenter, RN Zimmermann, P Garin-Chesa,

LJ Old & WJ Rettig 1999 Fibroblast activation protein: A dual-specificity serine protease expressed in reactive human tumor stromal fibroblasts *Journal of Biological Chemistry* **274**: 36505-12.

9. Levy MT, GW McCaughan, CA Abbott, JE Park, AM Cunningham, E Muller, WJ Rettig & MD Gorrell 1999 Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis *Hepatology* **29**: 1768-78.

10. De Meester I, S Korom, J Van Damme & S Scharpé 1999 CD26, let it cut or cut it down *Immunology Today* **20**: 367-75.

11. Natural substrates of dipeptidyl peptidase IV. De Meester I, C Durinx, G Bal, P Proost, S Struyf, F Goossens, K Augustyns & S Scharpé. 2000, in *Cellular Peptidases in Immune Functions and Diseases II*, J Langner & S Ansorge, Editor. Kluwer: New York. p. 67-88.

12. Mentlein R 1999 Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides *Regulatory Peptides* **85**: 9-24.

13. Morrison ME, S Vijayasaradhi, D Engelstein, AP Albino & AN Houghton 1993 A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase *Journal of Experimental Medicine* **177**: 1135-43.

14. Mueller SC, G Ghersi, SK Akiyama, QXA Sang, L Howard, M Pineiro-Sanchez, H Nakahara, Y Yeh & WT Chen 1999 A novel protease-docking function of integrin at invadopodia *Journal of Biological Chemistry* **274**: 24947-52.

15. Holst JJ & CF Deacon 1998 Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes *Diabetes* **47**: 1663-70.

16. Marguet D, L Baggio, T Kobayashi, AM Bernard, M Pierres, PF Nielsen, U Ribel, T Watanabe, DJ Drucker & N

Wagtmann 2000 Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 *Proceedings of the National Academy of Sciences of the United States of America* **97**: 6874-9.

17. Ohtsuki T, H Tsuda & C Morimoto 2000 Good or evil: CD26 and HIV infection *Journal of Dermatological Science* **22**: 152-60.

18. Wesley UV, AP Albino, S Tiwari & AN Houghton 1999 A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells *Journal of Experimental Medicine* **190**: 311-22.

19. Korom S, I De Meester, THW Stadlbauer, A Chandraker, M Schaub, MH Sayegh, A Belyaev, A Haemers, S Scharpé & JW Kupiecweglinski 1997 Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients *Transplantation* **63**: 1495-500.

20. Tanaka S, T Murakami, H Horikawa, M Sugiura, K Kawashima & T Sugita 1997 Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV *International Journal of Immunopharmacology* **19**: 15-24.

21. Augustyns K, G Bal, G Thonus, A Belyaev, XM Zhang, W Bollaert, AM Lambeir, C Durinx, F Goossens & A Haemers 1999 The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors *Current Medicinal Chemistry* **6**: 311-27.

22. Hinke SA, JA Pospisilik, HU Demuth, S Mannhart, K Kuhn-Wache, T Hoffmannn, E Nishimura, RA Pederson & CHS McIntosh 2000 Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon - Characterization of glucagon degradation products and DPIV-resistant analogs *Journal of Biological Chemistry* **275**: 3827-34.

23. Korom S, I De Meester, A Coito, E Graser, HD Volk, K Schwemmle, S Scharpe & JW Kupiec-Weglinski 1999 Immunomodulatory influence of CD26 dipeptidylpeptidase IV

during acute and accelerated rejection *Langenbecks Archives of Surgery* **1**: 241-5.

24. Tavares W, DJ Drucker & PL Brubaker 2000 Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats *American Journal of Physiology Endocrinology and Metabolism* **278**: E134-E9.

25. David F, AM Bernard, M Pierres & D Marguet 1993 Identification of serine 624, aspartic acid 702, and histidine 734 as the catalytic triad residues of mouse dipeptidyl-peptidase IV (CD26). A member of a novel family of nonclassical serine hydrolases *J Biol Chem* **268**: 17247-52.

26. Ogata S, Y Misumi, E Tsuji, N Takami, K Oda & Y Ikehara 1992 Identification of the active site residues in dipeptidyl peptidase IV by affinity labeling and site-directed mutagenesis *Biochemistry* **31**: 2582-7.

27. Dipeptidyl peptidase IV (DPPIV/CD26): biochemistry and control of cell-surface expression. Trugnan G, T Ait-Slimane, F David, L Baricault, T Berbar, C Lenoir & C Sapin. 1997, in *Cell-Surface Peptidases in Health and Disease*, AJ Kenny & CM Boustead, Editor. BIOS Scientific Publishers: Oxford. p. 203-17.

28. Steeg C, U Hartwig & B Fleischer 1995 Unchanged signaling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity *Cell Immunol* **164**: 311-5.

29. Fülop V, Z Bocskei & L Polgar 1998 Prolyl oligopeptidase - an unusual beta-propeller domain regulates proteolysis *Cell* **94**: 161-70.

30. Ausubel FM, R Brent, RE Kingston, DD Moore, JG Seidman, JA Smith & K Struhl, ed. Current Protocols in Molecular Biology. 1998, John Wiley & Sons: USA.

31. Molecular cloning: a laboratory manual. Sambrook J, EF Fritsch & T Maniatis. 1989. 2nd ed., Cold Spring Harbor: Cold Spring Harbor Laboratory Press.

32. Augustyns KJL, AM Lambeir, M Borloo, I Demeester, I Vedernikova, G Vanhoof, D Hendriks, S Scharpe & A Haemers 1997 Pyrrolidides - synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV *European Journal of Medicinal Chemistry* **32**: 301-9.

33. Stockel-Maschek A, C Mrestani-Klaus, B Stiebitz, HU Demuth & K Neubert 2000 Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases *Biochimica et Biophysica Acta - Protein Structure & Molecular Enzymology* **1479**: 15-31.

34. Schön E, I Born, HU Demuth, J Faust, K Neubert, T Steinmetzer, A Barth & S Ansorge 1991 Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes *Biological Chemistry Hoppe Seyler* **372**: 305-11.

35. Coligan JE, AM Kruisbeek, DH Margulies, EM Shevach & W Strober, eds. Current Protocols in Immunology. 1998, John Wiley & Sons: USA.

36. Fibroblast activation protein. Rettig WJ. 1998, in *Handbook of Proteolytic Enzymes*, AJ Barrett, ND Rawlings & JF Woessner, Editor. Academic Press: San Diego. p. 387-9.

CLAIMS

1. A peptide which comprises:

(a) the sequence shown in SEQ ID NO:2; or

(b) the amino acid sequences: $His^{833}GlyTrpSerTyrGlyGlyPheLeu$; $Leu^{913}AspGluAsnValHisPhePhe$; $Glu^{944}ArgHisSerIleArg$ and $Phe^{350}ValIleGlnGluGluPhe$, and which has the substrate specificity of the sequence shown in SEQ ID NO:2;or

(c) the sequence which has at least 60% identity with the sequence shown in SEQ ID NO:2, and which has the substrate specificity of the sequence shown in SEQ ID NO:2; or

(d) the sequence shown in SEQ ID NO:4.

2. A peptide according to claim 1 (c), wherein the amino acid identity is at least 75%.

3. A peptide according to claim 1 (c) wherein the amino acid identity is at least 95%.

4. A fragment of the sequence shown in SEQ ID NO:2 which has the substrate specificity of the sequence shown in SEQ ID NO:2.

5. A fragment according to claim 4 which comprises part of the sequence shown in SEQ ID NO:2.

6. A fusion protein comprising the amino acid sequence shown in SEQ ID NO:2 linked with a further amino acid sequence, the fusion protein having the substrate specificity of the sequence shown in SEQ ID NO:2.

7. A fusion protein according to claim 6 wherein the further amino acid sequence is selected from the group

consisting of GST, V5 epitope and His tag.

8. A method of identifying a molecule capable of inhibiting cleavage of a substrate by DPP9 comprising the following steps:

(a) contacting DPP9 with the molecule;

(b) contacting DPP9 of step (a) with a substrate capable of being cleaved by DPP9, in conditions sufficient for cleavage of the substrate by DPP9; and

(c) detecting substrate not cleaved by DPP9, to identify that the molecule is capable of inhibiting cleavage of the substrate by DPP9.

9. A method of identifying a molecule capable of inhibiting specifically, the cleavage of a substrate by DPP9, the method comprising the following steps:

(a) contacting DPP9 and a further protease with the molecule;

(b) contacting DPP9 and the further protease of step (a) with a substrate capable of being cleaved by DPP9 and the further protease, in conditions sufficient for cleavage of the substrate by DPP9 and the further protease; and

(c) detecting substrate not cleaved by DPP9, but cleaved by the further protease, to identify that the molecule is capable of inhibiting specifically, the cleavage of the substrate by DPP9.

10. A method of reducing or inhibiting the catalytic activity of DPP9, the method comprising the step of contacting DPP9 with an inhibitor of DPP9 catalytic activity.

11. A method of cleaving a substrate comprising the step of contacting the substrate with DPP9 in conditions sufficient for cleavage of the substrate by DPP9.

12. A nucleic acid molecule which:

(a) encodes the sequence shown in SEQ ID NO:2; or

(b) consists of the sequence shown in SEQ ID NO:1; or

(c) is capable of hybridizing to a nucleic acid molecule consisting of the sequence shown in SEQ ID NO:1 in stringent conditions, and which encodes a peptide which has the substrate specificity of the sequence shown in SEQ ID NO:2; or

(d) consists of the sequence shown in SEQ ID NO:3.

13. A nucleic acid molecule according to claim 12 (c) wherein the molecule is capable of hybridising in high stringent conditions.

14. A nucleic acid molecule according to claim 12 which is capable of hybridising to a gene which is located at band p13.3 on human chromosome 19.

15. A nucleic acid molecule according to claim 12 which does not contain 5′ or 3′ untranslated regions.

16. A fragment of a nucleic acid molecule consisting of the sequence shown in SEQ ID NO:1, which encodes a peptide which has the substrate specificity of the sequence shown in SEQ ID NO:2.

17. A fragment according to claim 16 which consists of part of the sequence shown in SEQ ID NO:1.

18. A vector comprising a nucleic acid molecule according to claim 12.

19. A cell comprising a vector according to claim 18.

20. A composition comprising a peptide according to claim 1.

21. An antibody which is capable of binding to a peptide according to claim 1.

22. An antibody according to claim 21 which is produced by a hybridoma cell.

23. A hybridoma cell capable of making an antibody according to claim 22.

24. A peptide comprising the sequence shown in SEQ ID NO: 7.

25. A nucleic acid molecule comprising the sequence shown in SEQ ID NO:8.

Table 1

FORWARD Primer name	Primer length	Primer sequence (5'- 3')
GDD pr 1f	24mer	GTG GAG ATC GAG GAC CAG GTG GAG
GDD pr 2f	24mer	CAA AGT GAG GAA AAA TGC ACT CCG
GDD pr 2a	24mer	TGA GGA AAA ATG CAC TCC GAG CAG
GDD pr 3f	24mer	AAA CTG GCT GAG TTC CAG ACT GAC
GDD pr 5f	24mer	CGG GGA AGG TGA GCA GAG CCT GAC
GDD pr 6f	24mer	AGA AGC ACC CCA CCG TCC TCT TTG
GDD pr 11f	24mer	GAG AAG GAG CTG GTG CAG CCC TTC
GDD pr 12f	24mer	TCA GAG GGA GAG GAC GAG CTC TGC
GDD pr 14f	24mer	CCG CTT CCA GGT GCA GAA GCA CTC
GDD pr 15f	24mer	CTA CGA CTT CCA CAG CGA GAG TGG
GDD pr 16f	25mer	GAT GAG TCC GAG GTG GAG GTC ATT C

REVERSE Primer name	Primer length	Primer sequence (5'- 3')
GDD pr 1r	24mer	GCT CAG AGG TAT TCC TGT AGA AAG
GDD pr 4r	24mer	CCC ATG TTG GCC AGG CTG GTC TTG
GDD pr 7r	24mer	AGG ACC AGC CAT GGA TGG CAA CTC
GDD pr 8r	24mer	CCG CTC AGC TTG TAG ACG TGC ACG
GDD pr 9r	24mer	TCA TTC TCT GTG CTC GGG ATG AAC
GDD pr 13r	24mer	GCA CAT CCG AGC GCG TGT GGA AAT
GDD pr 17r	24mer	TGG GAG AAG CCG GGC GTG GTG AGG
GDD pr 18r	25mer	GCG GTC GAA CTC TTC CTG TAT GAC G
5'RACE Primer name		
GDD GSP 1.1	18mer	TGA AGG AGA AGA AGG CAG
GDD GSP 2.1	24mer	CCT GAG CAC TGG GTC TTG ATT TCC
5' RACE Abridged Anchor Primer (AAP)	36mer	GGC CAC GCG TCG ATC ATG ACG GGI IGG GII GGG IIG



Figure 1


Computer Predicted GDD cDNA (3.6 kb in size)
GDD pr2Fa
GDD pr2F
GDD pr14F
GDDpr15F
GDD pr3F
GDD pr7R
GDD pr1R
GDD pr4R
TAA
ATG
EXON (based on the computer predicted sequence)
1
2
4
8
16
19
DDP4-like-1b (1.9 kb in size)
GDD pr15F
GDD pr7R
DDP4-like-2a (1.6 kb in size)
GDD pr3F
GDD pr1R
DDP4-like-2c (458 bp in size)
AAP
GDD GSP2.1

Figure 2


GDDb 6F.seq
GDDb M13R.seq
GDD 1R.seq
GDDd M13R.seq
GDDb 7R.seq
GDDd 7R.seq
GDDb 12F.seq
GDDd 12F.seq
GDDb 13R.seq
GDDd 13R.seq
GDDd 13R.seq
GDDd 17R.seq
GDDb M13F.seq
GDDb 3F.seq
GDDd 16F.seq
GDDb 9 R.seq
GDDd 15F.seq
GDDd 9R.seq
GDDd M13F.seq
GDDd 18R.seq
GDD RACE M13R.seq
GDD RACE M13F.seq
324
454
634
770
884
1,010
1,226
1,416
1,560
1,700
1,874
2,034
2,495
Diagram key
Hole in contig
Single fragment
Multiple fragments same direction
Both strands
Both strands plus

Figure 3

```
          10                  30                  50
  1 CGGCGGGTCCCCTGTGTCCGCCGCGGCTGTCGTCCCCCGCTCCCGCCACTTCCGGGGTCG   60
  1 R  R  V  P  C  V  R  R  G  C  R  P  P  L  P  P  L  P  G  S    20

          70                  90                  110
 61 CAGTCCCGGGCATGGAGCCGCGACCGTGAGGCGCCGCTGGACCCGGGACGACCTGCCCAG  120
 21 Q  S  R  A  W  S  R  D  R  E  A  P  L  D  P  G  R  P  A  Q    40

         130                 150                 170
121 TCCGGCCGCCGCCCCACGTCCCGGTCTGTGTCCCACGCCTGCAGCTGGAATGGAGGCTCT  180
 41 S  G  R  R  P  T  S  R  S  V  S  H  A  C  S  W  N  G  G  S    60

         190                 210                 230
181 CTGGACCCTTTAGAAGGCACCCCTGCCCTCCTGAGGTCAGCTGAGCGGTTAATGCGGAAG  240
 61 L  D  P  L  E  G  T  P  A  L  L  R  S  A  E  R  L  M  R  K    80

         250                 270                 290
241 GTTAAGAAACTGCGCCTGGACAAGGAGAACACCGGAAGTTGGAGAAGCTTCTCGCTGAAT  300
 81 V  K  K  L  R  L  D  K  E  N  T  G  S  W  R  S  F  S  L  N   100

         310                 330                 350
301 TCCGAGGGGGCTGAGAGGATGGCCACCACCGGGACCCCAACGGCCGACCGAGGCGACGCA  360
101 S  E  G  A  E  R  M  A  T  T  G  T  P  T  A  D  R  G  D  A   120

         370                 390                 410
361 GCCGCCACAGATGACCCGGCCGCCCGCTTCCAGGTGCAGAAGCACTCGTGGGACGGGCTC  420
121 A  A  T  D  D  P  A  A  R  F  Q  V  Q  K  H  S  W  D  G  L   140

         430                 450                 470
421 CGGAGCATCATCCACGGCAGCCGCAAGTACTCGGGCCTCATTGTCAACAAGGCGCCCCAC  480
141 R  S  I  I  H  G  S  R  K  Y  S  G  L  I  V  N  K  A  P  H   160

         490                 510                 530
481 GACTTCCAGTTTGTGCAGAAGACGGATGAGTCTGGGCCCCACTCCCACCGCCTCTACTAC  540
161 D  F  Q  F  V  Q  K  T  D  E  S  G  P  H  S  H  R  L  Y  Y   180

         550                 570                 590
541 CTGGGAATGCCATATGGCAGCCGGGAGAACTCCCTCCTCTACTCTGAGATTCCCAAGAAG  600
181 L  G  M  P  Y  G  S  R  E  N  S  L  L  Y  S  E  L  P  K  K   200

         610                 630                 650
601 GTCCGGAAAGAGGCTCTGCTGCTCCTGTCCTGGAAGCAGATGCTGGATCATTTCCAGGCC  660
201 V  R  K  E  A  L  L  L  L  S  W  K  Q  M  L  D  H  F  Q  A   220

         670                 690                 710
661 ACGCCCCACCATGGGGTCTACTCTCGGGAGGAGGAGCTGCTGAGGGAGCGGAAACGCCTG  720
221 T  P  H  H  G  V  Y  S  R  E  E  E  L  L  R  E  R  K  R  L   240

         730                 750                 770
721 GGGGTCTTCGGCATCACCTCCTACGACTTCCACAGCGAGAGTGGCCTCTTCCTCTTCCAG  780
241 G  V  F  G  I  T  S  Y  D  F  H  S  E  S  G  L  F  L  F  Q   260

         790                 810                 830
781 GCCAGCAACAGCCTCTTCCACTGCCGCGACGGCGGCAAGAACGGCTTCATGGTGTCCCCT  840
261 A  S  N  S  L  F  H  C  R  D  G  G  K  N  G  F  M  V  S  P   280

         850                 870                 890
841 ATGAAACCGCTGGAAATCAAGACCCAGTGCTCAGGGCCCCGGATGGACCCCAAAATCTGC  900
281 M  K  P  L  E  I  K  T  Q  C  S  G  P  R  M  D  P  K  I  C   300
```

FIGURE 4

```
          910                 930                 950
901  CCTGCCGACCCTGCCTTCTTCTCCTTCAACAATAACAGCGACCTGTGGGTGGCCAACATC   960
301  P  A  D  P  A  F  F  S  F  N  N  N  S  D  L  W  V  A  N  I    320

          970                 990                1010
961  GAGACAGGCGAGGAGCGGCGGCTGACCTTCTGCCACCAAGGTTTATCCAATGTCCTGGAT  1020
321  E  T  G  E  E  R  R  L  T  F  C  H  Q  G  L  S  N  V  L  D    340

         1030                1050                1070
1021 GACCCCAAGTCTGCGGGTGTGGCCACCTTCGTCATACAGGAAGAGTTCGACCGCTTCACT  1080
341  D  P  K  S  A  G  V  A  T  F  V  I  Q  E  E  F  D  R  F  T    360

         1090                1110                1130
1081 GGGTACTGGTGGTGCCCCACAGCCTCCTGGGAAGGTTCAGAGGGCCTCAAGACGCTGCGA  1140
361  G  Y  W  W  C  P  T  A  S  W  E  G  S  E  G  L  K  T  L  R    380

         1150                1170                1190
1141 ATCCTGTATGAGGAAGTCGATGAGTCCGAGGTGGAGGTCATTCACGTCCCCTCTCCTGCG  1200
381  I  L  Y  E  E  V  D  E  S  E  V  E  V  I  H  V  P  S  P  A    400

         1210                1230                1250
1201 CTAGAAGAAAGGAAGACGGACTCGTATCGGTACCCCAGGACAGGCAGCAAGAATCCCAAG  1260
401  L  E  E  R  K  T  D  S  Y  R  Y  P  R  T  G  S  K  N  P  K    420

         1270                1290                1310
1261 ATTGCCTTGAAACTGGCTGAGTTCCAGACTGACAGCCAGGGCAAGATCGTCTCGACCCAG  1320
421  I  A  L  K  L  A  E  F  Q  T  D  S  Q  G  K  I  V  S  T  Q    440

         1330                1350                1370
1321 GAGAAGGAGCTGGTGCAGCCCTTCAGCTCGCTGTTCCCGAAGGTGGAGTACATCGCCAGG  1380
441  E  K  E  L  V  Q  P  F  S  S  L  F  P  K  V  E  Y  I  A  R    460

         1390                1410                1430
1381 GCCGGGTGGACCCGGGATGGCAAATACGCCTGGGCCATGTTCCTGGACCGGCCCCAGCAG  1440
461  A  G  W  T  R  D  G  K  Y  A  W  A  M  F  L  D  R  P  Q  Q    480

         1450                1470                1490
1441 TGGCTCCAGCTCGTCCTCCTCCCCCCGGCCCTGTTCATCCCGAGCACAGAGAATGAGGAG  1500
481  W  L  Q  L  V  L  L  P  P  A  L  F  I  P  S  T  E  N  E  E    500

         1510                1530                1550
1501 CAGCGGCTAGCCTCTGCCAGAGCTGTCCCCAGGAATGTCCAGCCGTATGTGGTGTACGAG  1560
501  Q  R  L  A  S  A  R  A  V  P  R  N  V  Q  P  Y  V  V  Y  E    520

         1570                1590                1610
1561 GAGGTCACCAACGTCTGGATCAATGTTCATGACATCTTCTATCCCTTCCCCCAATCAGAG  1620
521  E  V  T  N  V  W  I  N  V  H  D  I  F  Y  P  F  P  Q  S  E    540

         1630                1650                1670
1621 GGAGAGGACGAGCTCTGCTTTCTCCGCGCCAATGAATGCAAGACCGGCTTCTGCCATTTG  1680
541  G  E  D  E  L  C  F  L  R  A  N  E  C  K  T  G  F  C  H  L    560

         1690                1710                1730
1681 TACAAAGTCACCGCCGTTTTAAAATCCCAGGGCTACGATTGGAGTGAGCCCTTCAGCCCC  1740
561  Y  K  V  T  A  V  L  K  S  Q  G  Y  D  W  S  E  P  F  S  P    580

         1750                1770                1790
1741 GGGGAAGATGAATTTAAGTGCCCCATTAAGGAAGAGATTGCTCTGACCAGCGGTGAATGG  1800
581  G  E  D  E  F  K  C  P  I  K  E  E  I  A  L  T  S  G  E  W    600
```

FIGURE 4

```
          1810                1830                1850
1801 GAGGTTTTGGCGAGGCACGGCTCCAAGATCTGGGTCAATGAGGAGACCAAGCTGGTGTAC 1860
 601 E  V  L  A  R  H  G  S  K  I  W  V  N  E  E  T  K  L  V  Y   620

          1870                1890                1910
1861 TTCCAGGGCACCAAGGACACGCCGCTGGAGCACCACCTCTACGTGGTCAGCTATGAGGCG 1920
 621 F  Q  G  T  K  D  T  P  L  E  H  H  L  Y  V  V  S  Y  E  A   640

          1930                1950                1970
1921 GCCGGCGAGATCGTACGCCTCACCACGCCCGGCTTCTCCCATAGCTGCTCCATGAGCCAG 1980
 641 A  G  E  I  V  R  L  T  T  P  G  F  S  H  S  C  S  M  S  Q   660

          1990                2010                2030
1981 AACTTCGACATGTTCGTCAGCCACTACAGCAGCGTGAGCACGCCGCCCTGCGTGCACGTC 2040
 661 N  F  D  M  F  V  S  H  Y  S  S  V  S  T  P  P  C  V  H  V   680

          2050                2070                2090
2041 TACAAGCTGAGCGGCCCCGACGACGACCCCCTGCACAAGCAGCCCCGCTTCTGGGCTAGC 2100
 681 Y  K  L  S  G  P  D  D  D  P  L  H  K  Q  P  R  F  W  A  S   700

          2110                2130                2150
2101 ATGATGGAGGCAGCCAGCTGCCCCCCGGATTATGTTCCTCCAGAGATCTTCCATTTCCAC 2160
 701 M  M  E  A  A  S  C  P  P  D  Y  V  P  P  E  I  F  H  F  H   720

          2170                2190                2210
2161 ACGCGCTCGGATGTGCGGCTCTACGGCATGATCTACAAGCCCCACGCCTTGCAGCCAGGG 2220
 721 T  R  S  D  V  R  L  Y  G  M  I  Y  K  P  H  A  L  Q  P  G   740

          2230                2250                2270
2221 AAGAAGCACCCCACCGTCCTCTTTGTATATGGAGGCCCCCAGGTGCAGCTGGTGAATAAC 2280
 741 K  K  H  P  T  V  L  F  V  Y  G  G  P  Q  V  Q  L  V  N  N   760

          2290                2310                2330
2281 TCCTTCAAAGGCATCAAGTACTTGCGGCTCAACACACTGGCCTCCCTGGGCTACGCCGTG 2340
 761 S  F  K  G  I  K  Y  L  R  L  N  T  L  A  S  L  G  Y  A  V   780

          2350                2370                2390
2341 GTTGTGATTGACGGCAGGGGCTCCTGTCAGCGAGGGCTTCGGTTCGAAGGGGCCCTGAAA 2400
 781 V  V  I  D  G  R  G  S  C  Q  R  G  L  R  F  E  G  A  L  K   800

          2410                2430                2450
2401 AACCAAATGGGCCAGGTGGAGATCGAGGACCAGGTGGAGGGCCTGCAGTTCGTGGCCGAG 2460
 801 N  Q  M  G  Q  V  E  I  E  D  Q  V  E  G  L  Q  F  V  A  E   820

          2470                2490                2510
2461 AAGTATGGCTTCATCGACCTGAGCCGAGTTGCCATCCATGGCTGGTCCTACGGGGGCTTC 2520
 821 K  Y  G  F  I  D  L  S  R  V  A  I  H  G  W  S  Y  G  G  F   840

          2530                2550                2570
2521 CTCTCGCTCATGGGGCTAATCCACAAGCCCCAGGTGTTCAAGGTGGCCATCGCGGGTGCC 2580
 841 L  S  L  M  G  L  I  H  K  P  Q  V  F  K  V  A  I  A  G  A   860

          2590                2610                2630
2581 CCGGTCACCGTCTGGATGGCCTACGACACAGGGTACACTGAGCGCTACATGGACGTCCCT 2640
 861 P  V  T  V  W  M  A  Y  D  T  G  Y  T  E  R  Y  M  D  V  P   880

          2650                2670                2690
2641 GAGAACAACCAGCACGGCTATGAGGCGGGTTCCGTGGCCCTGCACGTGGAGAAGCTGCCC 2700
 881 E  N  N  Q  H  G  Y  E  A  G  S  V  A  L  H  V  E  K  L  P   900

          2710                2730                2750
```

FIGURE 4

```
2701  AATGAGCCCAACCGCTTGCTTATCCTCCACGGCTTCCTGGACGAAAACGTGCACTTTTTC   2760
 901  N  E  P  N  R  L  L  I  L  H  G  F  L  D  E  N  V  H  F  F     920

           2770                2790                2810
2761  CACACAAACTTCCTCGTCTCCCAACTGATCCGAGCAGGGAAACCTTACCAGCTCCAGATC   2820
 921  H  T  N  F  L  V  S  Q  L  I  R  A  G  K  P  Y  Q  L  Q  I     940

           2830                2850                2870
2821  TACCCCAACGAGAGACACAGTATTCGCTGCCCCGAGTCGGGCGAGCACTATGAAGTCACG   2880
 941  Y  P  N  E  R  H  S  I  R  C  P  E  S  G  E  H  Y  E  V  T     960

           2890                2910                2930
2881  TTACTGCACTTTCTACAGGAATACCTCTGAGCCTGCCCACCGGGAGCCGCCACATCACAG   2940
 961  L  L  H  F  L  Q  E  Y  L  *

           2950                2970                2990
2941  CACAAGTGGCTGCAGCCTCCGCGGGGAACCAGGCGGGAGGGACTGAGTGGCCCGCGGGCC   3000


3001 CCAGTGAGGCACTTTGTCCCGCCC   3020
```

FIGURE 4



Figure 5

FIGURE 6


B (MTN Blot™)
heart
brain
placenta
lung
liver
skeletal muscle
kidney
pancreas
4.4kb
2.0 kb
1.8 kb
9.5kb
7.5kb
4.4kb
2.4kb
1.25kb
A (MTN Blot™ II)
spleen
thymus
prostate
testis
ovary
small intestine
colon(mucosal lining)
peripheral blood leukocytes
4.4kb
2.0 kb
9.5kb
7.5kb
4.4kb
2.4kb
1.25kb
GDD PROBE
β-actin control PROBE

FIGURE 7

mblddp9aa gap.txt

```
GAP of: hdpp9.aa  check: 7050  from: 1  to: 969

/home/rpag02/Cathy/tedfamily/PATENT/hdpp9.aa  [Unknown form]

to: mdpp9.aa  check: 4436  from: 1  to: 847

/home/rpag02/Cathy/tedfamily/PATENT/mdpp9.aa  [Unknown form]

Symbol comparison table: /dbase/gcg/gcgcore/data/rundata/nwsgappep.cmp
CompCheck: 1254

        Gap Weight:  3.000      Average Match:  0.540
     Length Weight:  0.100   Average Mismatch: -0.396

           Quality: 1179.7             Length:    969
             Ratio:  1.393               Gaps:      2
Percent Similarity: 94.215   Percent Identity: 90.555

hdpp9.aa x mdpp9.aa       October  5, 19101 16:00  ..


 51 SHACSWNGGSLDPLEGTPALLRSAERLMRKVKKLRLDKENTGSWRSFSLN 100

  1 .................................................P 1

101 SEGAERMATTGTPTADRGDAAATDDPAARFQVQKHSWDGLRSIIHGSRKY 150
    |::::||. .|....:...|:. ||.|||| ||||||||||||||||||
  2 SQEPQRMC.SGVSPVEQVAAGDMDDTAARFCVQKHSWDGLRSIIHGSRKS 50

151 SGLIVNKAPHDFQFVQKTDESGPHSHRLYYLGMPYGSRENSLLYSEIPKK 200
    ||||||.|||||||||||.||||||||||||||||||||||||||||||||
 51 SGLIVSKAPHDFQFVQKPDESGPHSHRLYYLGMPYGSRENSLLYSEIPKK 100

201 VRKEALLLLSWKQMLDHFQATPHHGVYSREEELLRERKRLGVFGITSYDF 250
    ||||||||||||||||||||||||||||||||||||||||||||||||||
101 VRKEALLLLSWKQMLDHFQATPHHGVYSREEELLRERKRLGVFGITSYDF 150
```

FIGURE 8


251 HSESGLFLFQASNSLFHCRDGGKNGFMVSPMKPLEIKTQCSGPRMDPKIC 300
151 HSESGLFLFQASNSLFHCRDGGKNGFMVSPMKPLEIKTQCSGPRMDPKIC 200
301 PADPAFFSFNNNSDLWVANIETGEERRLTFCHQGLSNVLDDPKSAGVATF 350
201 PADPAFFSFINNSDLWVANIETGEERRLTFCHQGSAGVLDNPKSAGVATF 250
351 VIQEEFDRFTGYWWCPTASWEGSQGLKTLRILYEEVDESEVEVIHVPSPA 400
251 VIQEEFDRFTGCWWCPTASWEGSEGLKTLRILYEEVDESEVEVIHVPSPA 300
401 LEERKTDSYRYPRTGSKNPKIALKLAEFQTDSQGKIVSTQEKELVQPFSS 450
301 LEERKTDSYRYPRTGSKNPKIALKLAELQTDHQGKIVSSCEKELVQPFSS 350
451 LFPKVEYIARAGWTRDGKYAWAMFLDRPQQWLQLVLLPPALFIPSTENEE 500
351 LFPKVEYIARAGWTRDGKYAWAMFLDRPQQRLQLVLLPPALFIPAVESEA 400
501 QRLASARAVPRNVQPYVVYEEVTNVWINVHDIFYPFPQSEGEDELCFLRA 550
401 QRQAAARAVPKNVQPFVIYEEVTNVWINVHDIFHPFPQAEGQQDFCFLRA 450
551 NECKTGFCHLYKVTAVLKSQGYDWSEPFSPGEDEFKCPIKEEIALTSGEW 600
451 NECKTGFCHLYRVTVELKTKDYDWTEPLSPTEGEFKCPIKEEVALTSGEW 500
601 EVLARHGSKIWVNEETKLVYFQGTKDTPLEHHLYVVSYEAAGEIVRLTTP 650

FIGURE 8

```
501 EVLSRHGSKIWVNEQTKLVYFQGTKDTPLEHHLYVVSYESAGEIVRLTTL 550

651 GFSHSCSMSQNFDMFVSHYSSVSTPPCVHVYKLSGPDDDPLHKQPRFWAS 700
    ||||||||||.||||||||||||||||||||||||||||||||||||||||
551 GFSHSCSMSQSFDMFVSHYSSVSTPPCVHVYKLSGPDDDPLHKQPRFWAS 600

701 MMEAASCPPDYVPPEIFHFHTRSDVRLYGMIYKPHALQPGKKHPTVLFVY 750
    |||||.|||||||||||||||.||.||||||||||.||||:||||||||||
601 MMEAANCPPDYVPPEIFHFHTRADVQLYGMIYKPHTLQPGRKHPTVLFVY 650

751 GGPQVQLVNNSFKGIKYLRLNTLASLGYAVVVIDGRGSCQRGLRFEGALK 800
    ||||||||||||||||||||||||||||||||||||||||||:||||||
651 GGPQVQLVNNSFKGIKYLRLNTLASLGYAVVVIDGRGSCQRGLHFEGALK 700

801 NQMGQVEIEDQVEGLQFVAEKYGFIDLSRVAIHGWSYGGFLSLMGLIHKP 850
    ||||||||||||||||:||||||||||||||||||||||||||||||||||
701 NQMGQVEIEDQVEGLQYVAEKYGFIDLSRVAIHGWSYGGFLSLMGLIHKP 750

851 QVFKVAIAGAPVTVWMAYDTGYTERYMDVPENNQHGYEAGSVALHVEKLP 900
    ||||||||||||||||||||||||||||||||||:||||||||||||||||
751 QVFKVAIAGAPVTVWMAYDTGYTERYMDVPENNQQGYEAGSVALHVEKLP 800

901 NEPNRLLILHGFLDENVHFFHTNFLVSQLIRAGKPYQLQIYPNERHSIRC 950
    ||||||||||||||||||||||||||||||||||||:      |: .
801 NEPNRLLILHGFLDENVHFFHTNFLVSQLIRAGKPYQLQV.....ASVTT 845

951 PESGEHYEVTLLHFLQEYL 969
    |:
846 PQ.................. 847
```

FIGURE 8

mBLdpp9 dnagap.b

```
 GAP of: dpp9patent.dna  check: 1968  from: 1  to: 3000

/home/rpag02/Cathy/tedfamily/PATENT/dpp9patent.dna  [Unknown form]

 to: mdpp9.dna  check: 672  from: 1  to: 2873

/home/rpag02/Cathy/tedfamily/PATENT/mdpp9.dna  [Unknown form]

 Symbol comparison table: /dbase/gcg/gcgcore/data/rundata/nwsgapdna.cmp
 CompCheck: 6876

        Gap Weight:  5.000      Average Match:  1.000
     Length Weight:  0.300   Average Mismatch:  0.000

           Quality: 2166.5             Length:   3172
             Ratio:  0.754               Gaps:      2
 Percent Similarity: 80.637   Percent Identity: 80.637

 dpp9patent.dna x mdpp9.dna October  5, 19101 16:00  ..


   251 TGCGCCTGGACAAGGAGAACACCGGAAGTTGGAGAAGCTTCTCGCTGAAT 300
                                                       |
     1 .....................................................GCCA 4

   301 TCCGAGGGGGCTGAGAGGATGGCCACCACCGGGACCCCAACGGCCGACCG 350
       ||  ||| | |  ||||||||     ||| ||||  | |  | |  || |
     5 TCACAGGAGCCCCAGAGGATG...TGCAGCGGGGTCTCCCCAGTTGAGCA 51

   351 AGGCGACGCAGCCGCCACAGATGACCCGGCCGCCCGCTTCCAGGTGCAGA 400
       |  | |||||  | ||  |||||| |||| || ||||||   |||||||
    52 GGTGGCCGCAGGGGACATGGATGACACGGCAGCACGCTTCTGTGTGCAGA 101
```

FIGURE 9


401 AGCACTCGTGGGACGGGCTCCGGAGCATCATCCACGGCAGCCGCAAGTAC 450
102 AGCACTCGTGGGATGGGCTGCGTAGCATTATCCACGGCAGTCGCAAGTCC 151
451 TCGGGCCTCATTGTCAACAAGGCGCCCCACGACTTCCAGTTTGTGCAGAA 500
152 TCGGGCCTCATTGTCAGCAAGGCCCCCCACGACTTCCAGTTTGTGCAGAA 201
501 GACGGATGAGTCTGGGCCCCACTCCCACCGCCTCTACTACCTGGGAATGC 550
202 GCCTGACGAGTCTGGCCCCCACTCTCACCGTCTCTATTACCTCGGAATGC 251
551 CATATGGCAGCCGGGAGAACTCCCTCCTCTACTCTGAGATTCCCAAGAAG 600
252 CTTACGGCAGCCGTGAGAACTCCCTCCTCTACTCCGAGATCCCCAAGAAA 301
601 GTCCGGAAAGAGGCTCTGCTGCTCCTGTCCTGGAAGCAGATGCTGGATCA 650
302 GTGCGGAAGGAGGCCCTGCTGCTGCTGTCCTGGAAGCAGATGCTGGACCA 351
651 TTTCCAGGCCACGCCCCACCATGGGGTCTACTCTCGGGAGGAGGAGCTGC 700
352 CTTCCAGGCCACACCCCACCATGGTGTCTACTCCCGAGAGGAGGAGCTAC 401
701 TGAGGGAGCGGAAACGCCTGGGGGTCTTCGGCATCACCTCCTACGACTTC 750
402 TGCGGGAGCGCAAGCGCCTGGGCGTCTTCGGAATCACCTCTTATGACTTC 451
751 CACAGCGAGAGTGGCCTCTTCCTCTTCCAGGCCAGCAACAGCCTCTTCCA 800
452 CACAGTGAGAGCGGCCTCTTCCTCTTCCAGGCCAGCAATAGCCTGTTCCA 501
801 CTGCCGCGACGGCGGCAAGAACGGCTTCATGGTGTCCCCTATGAAACCGC 850

FIGURE 9


502 CTGCAGGGATGGTGGCAAGAATGGCTTTATGGTGTCCCCGATGAAGCCAC 551
851 TGGAAATCAAGACCCAGTGCTCAGGGCCCCGGATGGACCCCAAAATCTGC 900
552 TGGAGATCAAGACTCAGTGTTCTGGGCCACGCATGGACCCCAAAATCTGC 601
901 CCTGCCGACCCTGCCTTCTTCTCCTTCAACAATAACAGCGACCTGTGGGT 950
602 CCCGCAGACCCTGCCTTCTTTTCCTTCATCAACAACAGTGATCTGTGGGT 651
951 GGCCAACATCGAGACAGGCGAGGAGCGGCGGCTGACCTTCTGCCACCAAG 1000
652 GGCAAACATCGAGACTGGGGAGGAACGGCGGCTCACCTTCTGTCACCAGG 701
1001 GTTTATCCAATGTCCTGGATGACCCCAAGTCTGCGGGTGTGGCCACCTTC 1050
702 GTTCAGCTGGTGTCCTGGACAATCCCAAATCAGCAGGCGTGGCCACCTTT 751
1051 GTCATACAGGAAGAGTTCGACCGCTTCACTGGGTACTGGTGGTGCCCCAC 1100
752 GTCATCCAGGAGGAGTTCGACCGCTTCACTGGGTGCTGGTGGTGCCCCAC 801
1101 AGCCTCCTGGGAAGGTTCAGAGGGCCTCAAGACGCTGCGAATCCTGTATG 1150
802 GGCCTCTTGGGAAGGCTCCGAAGGTCTCAAGACGCTGCGCATCCTATATG 851
1151 AGGAAGTCGATGAGTCCGAGGTGGAGGTCATTCACGTCCCCTCTCCTGCG 1200
852 AGGAAGTGGACGAGTCTGAAGTGGAGGTCATTCATGTGCCCTCCCCCGCC 901
1201 CTAGAAGAAAGGAAGACGGACTCGTATCGGTACCCCAGGACAGGCAGCAA 1250
902 CTGGAGGAGAGGAAGACGGACTCCTACCGCTACCCCAGGACAGGCAGCAA 951

FIGURE 9


1251 GAATCCCAAGATTGCCTTGAAACTGGCTGAGTTCCAGACTGACAGCCAGG 1300
952 GAACCCCAAGATTGCCCTGAAGCTGGCTGAGCTCCAGACGGACCATCAGG 1001
1301 GCAAGATCGTCTCGACCCAGGAGAAGGAGCTGGTGCAGCCCTTCAGCTCG 1350
1002 GCAAAATCGTGTCAAGCTGCGAGAAGGAACTGGTACAGCCATTCAGCTCC 1051
1351 CTGTTCCCGAAGGTGGAGTACATCGCCAGGGCCGGGTGGACCCGGGATGG 1400
1052 CTTTTCCCCAAAGTGGAGTACATCGCCCGGGCTGGCTGGACACGGGACGG 1101
1401 CAAATACGCCTGGGCCATGTTCCTGGACCGGCCCCAGCAGTGGCTCCAGC 1450
1102 CAAATATGCCTGGGCCATGTTCCTGGACCGTCCCCAGCAACGGCTTCAGC 1151
1451 TCGTCCTCCTCCCCCCGGCCCTGTTCATCCCGAGCACAGAGAATGAGGAG 1500
1152 TTGTCCTCCTGCCCCCTGCTCTCTTCATCCCGGCCGTTGAGAGTGAGGCC 1201
1501 CAGCGGCTAGCCTCTGCCAGAGCTGTCCCCAGGAATGTCCAGCCGTATGT 1550
1202 CAGCGGCAGGCAGCTGCCAGAGCCGTCCCCAAGAATGTGCAGCCCTTTGT 1251
1551 GGTGTACGAGGAGGTCACCAACGTCTGGATCAATGTTCATGACATCTTCT 1600
1252 CATCTATGAAGAAGTCACCAATGTCTGGATCAACGTCCACGACATCTTCC 1301
1601 ATCCCTTCCCCCAATCAGAGGGAGAGGACGAGCTCTGCTTTCTCCGCGCC 1650
1302 ACCCGTTTCCTCAGGCTGAGGGCCAGCAGGACTTTTGTTTCCTTCGTGCC 1351
1651 AATGAATGCAAGACCGGCTTCTGCCATTTGTACAAAGTCACCGCCGTTTT 1700
1352 AACGAATGCAAGACTGGCTTCTGCCACCTGTACAGGGTCACAGTGGAACT 1401

FIGURE 9


1701 AAAATCCCAGGGCTACGATTGGAGTGAGCCCTTCAGCCCCGGGGAAGATG 1750
1402 TAAAACCAAGGACTATGACTGGACGGAACCCCTCAGCCCTACAGAAGGTG 1451
1751 AATTTAAGTGCCCCATTAAGGAAGAGATTGCTCTGACCAGCGGTGAATGG 1800
1452 AGTTTAAGTGCCCCATCAAGGAGGAGGTCGCCCTGACCAGTGGCGAGTGG 1501
1801 GAGGTTTTGGCGAGGCACGGCTCCAAGATCTGGGTCAATGAGGAGACCAA 1850
1502 GAGGTCTTGTCGAGGCATGGCTCCAAGATCTGGGTCAACGAGCAGACGAA 1551
1851 GCTGGTGTACTTCCAGGGCACCAAGGACACGCCGCTGGAGCACCACCTCT 1900
1552 GCTGGTGTACTTTCAAGGTACAAAGGACACACCGCTGGAACATCACCTCT 1601
1901 ACGTGGTCAGCTATGAGGCGGCCGGCGAGATCGTACGCCTCACCACGCCC 1950
1602 ATGTGGTCAGCTACGAGTCAGCAGGCGAGATCGTGCGGCTCACCACGCTC 1651
1951 GGCTTCTCCCATAGCTGCTCCATGAGCCAGAACTTCGACATGTTCGTCAG 2000
1652 GGCTTCTCCCACAGCTGCTCCATGAGCCAGAGCTTCGACATGTTCGTGAG 1701
2001 CCACTACAGCAGCGTGAGCACGCCGCCCTGCGTGCACGTCTACAAGCTGA 2050
1702 TCACTACAGCAGTGTGAGCACGCCACCCTGTGTACATGTGTACAAGCTGA 1751
2051 GCGGCCCCGACGACGACCCCCTGCACAAGCAGCCCCGCTTCTGGGCTAGC 2100
1752 GCGGCCCCGATGATGACCCACTGCACAAGCAACCACGCTTCTGGGCCAGC 1801
2101 ATGATGGAGGCAGCCAGCTGCCCCCCGGATTATGTTCCTCCAGAGATCTT 2150
1802 ATGATGGAGGCAGCCAATTGCCCCCCAGACTATGTGCCCCCTGAGATCTT 1851

FIGURE 9


2151 CCATTTCCACACGCGCTCGGATGTGCGGCTCTACGGCATGATCTACAAGC 2200
1852 CCACTTCCACACCCGTGCAGACGTGCAGCTCTACGGCATGATCTACAAGC 1901
2201 CCCACGCCTTGCAGCCAGGGAAGAAGCACCCCACCGTCCTCTTTGTATAT 2250
1902 CACACACCCTGCAACCTGGGAGGAAGCACCCCACTGTGCTCTTTGTCTAT 1951
2251 GGAGGCCCCCAGGTGCAGCTGGTGAATAACTCCTTCAAAGGCATCAAGTA 2300
1952 GGGGGCCCACAGGTGCAGTTGGTGAACAACTCCTTTAAGGGCATCAAATA 2001
2301 CTTGCGGCTCAACACACTGGCCTCCCTGGGCTACGCCGTGGTTGTGATTG 2350
2002 CCTGCGGCTAAATACACTGGCATCCTTGGGCTATGCTGTGGTGGTGATCG 2051
2351 ACGGCAGGGGCTCCTGTCAGCGAGGGCTTCGGTTCGAAGGGGCCCTGAAA 2400
2052 ATGGTCGGGGCTCCTGTCAGCGGGGCCTGCACTTCGAGGGGGCCCTGAAA 2101
2401 AACCAAATGGGCCAGGTGGAGATCGAGGACCAGGTGGAGGGCCTGCAGTT 2450
2102 AATCAAATGGGCCAGGTGGAGATTGAGGACCAGGTGGAAGGCTTGCAGTA 2151
2451 CGTGGCCGAGAAGTATGGCTTCATCGACCTGAGCCGAGTTGCCATCCATG 2500
2152 CGTGGCTGAGAAGTATGGCTTCATTGACTTGAGCCGAGTCGCCATCCATG 2201
2501 GCTGGTCCTACGGGGGCTTCCTCTCGCTCATGGGGCTAATCCACAAGCCC 2550
2202 GCTGGTCCTACGGCGGCTTCCTCTCACTCATGGGGCTCATCCACAAGCCA 2251
2551 CAGGTGTTCAAGGTGGCCATCGCGGGTGCCCCGGTCACCGTCTGGATGGC 2600

FIGURE 9

FIGURE. 10



Rat Multiple Tissue Northern Blot hybridised with a human DPP9 probe of 2,589 bases. The hybridisation was carried out overnight at 60° C.


2252 CAAGTGTTCAAGGTAGCCATTGCGGGCGCTCCTGTCACTGTGTGGATGGC 2301
2601 CTACGACACAGGGTACACTGAGCGCTACATGGACGTCCCTGAGAACAACC 2650
2302 CTATGACACAGGGTACACGGAACGATACATGGATGTCCCCGAAAATAACC 2351
2651 AGCACGGCTATGAGGCGGGTTCCGTGGCCCTGCACGTGGAGAAGCTGCCC 2700
2352 AGCAAGGCTATGAGGCAGGGTCTGTAGCCCTGCATGTGGAGAAGCTGCCC 2401
2701 AATGAGCCCAACCGCTTGCTTATCCTCCACGGCTTCCTGGACGAAAACGT 2750
2402 AATGAGCCTAACCGCCTGCTTATCCTCCACGGCTTCCTGGACGAGAACGT 2451
2751 GCACTTTTTCCACACAAACTTCCTCGTCTCCCAACTGATCCGAGCAGGGA 2800
2452 TCACTTCTTCCACACAAATTTCCTGGTGTCCCAGCTGATCCGAGCAGGAA 2501
2801 AACCTTACCAGCTCCAGAT..CTACCCCAACGAGAGACACAGTATTCGCT 2848
2502 AGCCATACCAGCTTCAGGTTGCATCAGTGACAACACCTCAGTGACTACCC 2551
2849 GCCCCGAGTCGGGCGAGCACTATGAAGTCACGTTACTGCACTTTCTACAG 2898
2552 CTCACTAAGACCCCAGTTTTGATGAACCCACTTGGCTACAGGCATGGGAG 2601
2899 GAATACCTCTGAGCCTGCCCACCGGGAGCCGCCACATCACAGCACAAGTG 2948
2602 TGCCCCCCAATGATTAGAGACCCAAGAGCAGTTGCCTGAGGGAGAGGACA 2651
2949 GCTGCAGCCTCCGCGGGGAACCAGGCGGGAGGGACTGAGTGGCCCGCGGG 2998
2652 TTTAAAGGTCCAGGACTGAATCTACCCAAACGAGAGACATAGCATCCGCT 2701
2999 CC..... 3000
2702 GCCGCGAGTCCGGAGAGCATTACGAGGTGACGCTGCTGCACTTTCTGCAG 2751

FIGURE 9



DPP9 PCR products.
Lane 2; generated from CEM cell line RNA using DPP9 primers 22F and 3' end.
Lane 4; the same primers with Xbal sites on th ends.

FIGURE 11



Figure showing DPP9 PCR products from liver of six mice (numbered 1 to 6)
and the largest human DPP9 fragment.

FIGURE 12



FIGURE 12.

Untitled.ST25.txt
SEQUENCE LISTING

<110> THE UNIVERSITY OF SYDNEY

<120> DIPEPTIDYL PEPTIDASES

<130> FP15217

<160> 8

<170> PatentIn version 3.1

<210> 1
<211> 3000
<212> DNA
<213> Homo sapiens

<400> 1
cggcgggtcc cctgtgtccg ccgcggctgt cgtcccccgc tcccgccact tccggggtcg 60

cagtcccggg catggagccg cgaccgtgag gcgccgctgg acccgggacg acctgcccag 120

tccggccgcc gccccacgtc ccggtctgtg tcccacgcct gcagctggaa tggaggctct 180

ctggaccctt tagaaggcac ccctgccctc ctgaggtcag ctgagcggtt aatgcggaag 240

gttaagaaac tgcgcctgga caaggagaac accggaagtt ggagaagctt ctcgctgaat 300

tccgaggggg ctgagaggat ggccaccacc gggaccccaa cggccgaccg aggcgacgca 360

gccgccacag atgacccggc cgcccgcttc caggtgcaga agcactcgtg ggacgggctc 420

cggagcatca tccacggcag ccgcaagtac tcgggcctca ttgtcaacaa ggcgccccac 480

gacttccagt ttgtgcagaa gacggatgag tctgggcccc actcccaccg cctctactac 540

ctgggaatgc catatggcag ccgggagaac tccctcctct actctgagat tcccaagaag 600

gtccggaaag aggctctgct gctcctgtcc tggaagcaga tgctggatca tttccaggcc 660

acgccccacc atggggtcta ctctcgggag gaggagctgc tgagggagcg gaaacgcctg

720

ggggtcttcg gcatcacctc ctacgacttc cacagcgaga gtggcctctt cctcttccag
780

gccagcaaca gcctcttcca ctgccgcgac ggcggcaaga acggcttcat ggtgtcccct
840

atgaaaccgc tggaaatcaa gacccagtgc tcagggcccc ggatggaccc caaaatctgc
900

cctgccgacc ctgccttctt ctccttcaac aataacagcg acctgtgggt ggccaacatc
960

gagacaggcg aggagcggcg gctgaccttc tgccaccaag gtttatccaa tgtcctggat
1020

gaccccaagt ctgcgggtgt ggccaccttc gtcatacagg aagagttcga ccgcttcact
1080

gggtactggt ggtgccccac agcctcctgg gaaggttcag agggcctcaa gacgctgcga
1140

atcctgtatg aggaagtcga tgagtccgag gtggaggtca ttcacgtccc ctctcctgcg
1200

ctagaagaaa ggaagacgga ctcgtatcgg taccccagga caggcagcaa gaatcccaag
1260

attgccttga aactggctga gttccagact gacagccagg gcaagatcgt ctcgacccag
1320

gagaaggagc tggtgcagcc cttcagctcg ctgttcccga aggtggagta catcgccagg
1380

gccgggtgga cccgggatgg caaatacgcc tgggccatgt tcctggaccg gccccagcag
1440

tggctccagc tcgtcctcct ccccccggcc ctgttcatcc cgagcacaga gaatgaggag
1500

cagcggctag cctctgccag agctgtcccc aggaatgtcc agccgtatgt ggtgtacgag
1560

gaggtcacca acgtctggat caatgttcat gacatcttct atcccttccc ccaatcagag
1620

ggagaggacg agctctgctt tctccgcgcc aatgaatgca agaccggctt ctgccatttg
1680

tacaaagtca ccgccgtttt aaaatcccag ggctacgatt ggagtgagcc cttcagcccc
1740

ggggaagatg aatttaagtg ccccattaag gaagagattg ctctgaccag cggtgaatgg
1800

gaggttttgg cgaggcacgg ctccaagatc tgggtcaatg aggagaccaa gctggtgtac
1860

ttccagggca ccaaggacac gccgctggag caccacctct acgtggtcag ctatgaggcg
1920

gccggcgaga tcgtacgcct caccacgccc ggcttctccc atagctgctc catgagccag
1980

aacttcgaca tgttcgtcag ccactacagc agcgtgagca cgccgccctg cgtgcacgtc
2040

tacaagctga gcggccccga cgacgacccc ctgcacaagc agccccgctt ctgggctagc
2100

atgatggagg cagccagctg ccccccggat tatgttcctc cagagatctt ccatttccac
2160

acgcgctcgg atgtgcggct ctacggcatg atctacaagc cccacgcctt gcagccaggg
2220

aagaagcacc ccaccgtcct ctttgtatat ggaggccccc aggtgcagct ggtgaataac
2280

tccttcaaag gcatcaagta cttgcggctc aacacactgg cctccctggg ctacgccgtg
2340

gttgtgattg acggcagggg ctcctgtcag cgagggcttc ggttcgaagg ggccctgaaa
2400

aaccaaatgg gccaggtgga gatcgaggac caggtggagg gcctgcagtt cgtggccgag
2460

aagtatggct tcatcgacct gagccgagtt gccatccatg gctggtccta cgggggcttc
2520

ctctcgctca tggggctaat ccacaagccc caggtgttca aggtggccat cgcgggtgcc
2580

ccggtcaccg tctggatggc ctacgacaca gggtacactg agcgctacat ggacgtccct
2640

gagaacaacc agcacggcta tgaggcgggt tccgtggccc tgcacgtgga gaagctgccc
2700

aatgagccca accgcttgct tatcctccac ggcttcctgg acgaaaacgt gcacttttc
2760

cacacaaact tcctcgtctc ccaactgatc cgagcaggga aaccttacca gctccagatc
2820

taccccaacg agagacacag tattcgctgc cccgagtcgg gcgagcacta tgaagtcacg
2880

ttactgcact ttctacagga atacctctga gcctgcccac cgggagccgc cacatcacag
2940

cacaagtggc tgcagcctcc gcggggaacc aggcgggagg gactgagtgg cccgcgggcc
3000

<210> 2
<211> 969
<212> PRT
<213> Homo sapiens

<400> 2

Arg Arg Val Pro Cys Val Arg Arg Gly Cys Arg Pro Pro Leu Pro Pro
1 5 10 15

Leu Pro Gly Ser Gln Ser Arg Ala Trp Ser Arg Asp Arg Glu Ala Pro
20 25 30

Leu Asp Pro Gly Arg Pro Ala Gln Ser Gly Arg Arg Pro Thr Ser Arg
35 40 45

Ser Val Ser His Ala Cys Ser Trp Asn Gly Gly Ser Leu Asp Pro Leu
50 55 60

Glu Gly Thr Pro Ala Leu Leu Arg Ser Ala Glu Arg Leu Met Arg Lys
65 70 75 80

Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser Trp Arg Ser
85 90 95

Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr Thr Gly Thr
100 105 110

Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp Pro Ala Ala
115 120 125

Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg Ser Ile Ile
130 135 140

His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys Ala Pro His
145 150 155 160

Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro His Ser His
165 170 175

Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu Asn Ser Leu
180 185 190

Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala Leu Leu Leu
195 200 205

Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr Pro His His
210 215 220

Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg Leu
225 230 235 240

Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu Ser Gly Leu
245 250 255

Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg Asp Gly Gly
260 265 270

Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu Ile Lys Thr
275 280 285

Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro Ala Asp Pro
290 295 300

Ala Phe Phe Ser Phe Asn Asn Asn Ser Asp Leu Trp Val Ala Asn Ile
305 310 315 320

Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln Gly Leu Ser
325 330 335

Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr Phe Val Ile
340 345 350

Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys Pro Thr Ala
355 360 365

Ser Trp Glu Gly Ser Gln Gly Leu Lys Thr Leu Arg Ile Leu Tyr Glu
370 375 380

Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro Ser Pro Ala
385 390 395 400

Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg Thr Gly Ser
405 410 415

Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln Thr Asp Ser
420 425 430

Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val Gln Pro Phe
435 440 445

Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr
450 455 460

Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg Pro Gln Gln
465 470 475 480

Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile Pro Ser Thr
485 490 495

Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val Pro Arg Asn
500 505 510

Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val Trp Ile Asn
515 520 525

Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly Glu Asp Glu
530 535 540

Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe Cys His Leu
545 550 555 560

Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp Trp Ser Glu
565 570 575

Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile Lys Glu Glu
580 585 590

Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg His Gly Ser
595 600 605

Lys Ile Trp Val Asn Glu Glu Thr Lys Leu Val Tyr Phe Gln Gly Thr
610 615 620

Lys Asp Thr Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Glu Ala
625 630 635 640

Ala Gly Glu Ile Val Arg Leu Thr Thr Pro Gly Phe Ser His Ser Cys
645 650 655

Ser Met Ser Gln Asn Phe Asp Met Phe Val Ser His Tyr Ser Ser Val
660 665 670

Ser Thr Pro Pro Cys Val His Val Tyr Lys Leu Ser Gly Pro Asp Asp
675 680 685

Asp Pro Leu His Lys Gln Pro Arg Phe Trp Ala Ser Met Met Glu Ala
690 695 700

Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro Glu Ile Phe His Phe His
705 710 715 720

Thr Arg Ser Asp Val Arg Leu Tyr Gly Met Ile Tyr Lys Pro His Ala
725 730 735

Leu Gln Pro Gly Lys Lys His Pro Thr Val Leu Phe Val Tyr Gly Gly
740 745 750

Pro Gln Val Gln Leu Val Asn Asn Ser Phe Lys Gly Ile Lys Tyr Leu
755 760 765

Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr Ala Val Val Val Ile Asp
770 775 780

Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg Phe Glu Gly Ala Leu Lys
785 790 795 800

Asn Gln Met Gly Gln Val Glu Ile Glu Asp Gln Val Glu Gly Leu Gln
805 810 815

Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp Leu Ser Arg Val Ala Ile
820 825 830

His Gly Trp Ser Tyr Gly Gly Phe Leu Ser Leu Met Gly Leu Ile His
835 840 845

Lys Pro Gln Val Phe Lys Val Ala Ile Ala Gly Ala Pro Val Thr Val
850 855 860

Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu Arg Tyr Met Asp Val Pro
865 870 875 880

Glu Asn Asn Gln His Gly Tyr Glu Ala Gly Ser Val Ala Leu His Val
885 890 895

Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu Leu Ile Leu His Gly Phe
900 905 910

Leu Asp Glu Asn Val His Phe Phe His Thr Asn Phe Leu Val Ser Gln
915 920 925

Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu Gln Ile Tyr Pro Asn Glu
930 935 940

Arg His Ser Ile Arg Cys Pro Glu Ser Gly Glu His Tyr Glu Val Thr
945 950 955 960

Leu Leu His Phe Leu Gln Glu Tyr Leu
965

<210> 3
<211> 3287
<212> DNA
<213> Mus musculus

<400> 3
ccatcacagg agccccagag gatgtgcagc ggggtctccc cagttgagca ggtggccgca
60

ggggacatgg atgacacggc agcacgcttc tgtgtgcaga agcactcgtg ggatgggctg
120

cgtagcatta tccacggcag tcgcaagtcc tcgggcctca ttgtcagcaa ggccccccac
180

gacttccagt ttgtgcagaa gcctgacgag tctggccccc actctcaccg tctctattac
240

ctcggaatgc cttacggcag ccgtgagaac tccctcctct actccgagat ccccaagaaa
300

gtgcggaagg aggccctgct gctgctgtcc tggaagcaga tgctggacca cttccaggcc
360

acaccccacc atggtgtcta ctcccgagag gaggagctac tgcgggagcg caagcgcctg
420

ggcgtcttcg gaatcacctc ttatgacttc cacagtgaga gcggcctctt cctcttccag
480

gccagcaata gcctgttcca ctgcagggat ggtggcaaga atggctttat ggtgtccccg
540

atgaagccac tggagatcaa gactcagtgt tctgggccac gcatggaccc caaaatctgc
600

cccgcagacc ctgccttctt ttccttcatc aacaacagtg atctgtgggt ggcaaacatc
660

gagactgggg aggaacggcg gctcaccttc tgtcaccagg gttcagctgg tgtcctggac
720

aatcccaaat cagcaggcgt ggccaccttt gtcatccagg aggagttcga ccgcttcact
780

gggtgctggt ggtgccccac ggcctcttgg gaaggctccg aaggtctcaa gacgctgcgc
840

atcctatatg aggaagtgga cgagtctgaa gtggaggtca ttcatgtgcc ctccccgcc
900

ctggaggaga ggaagacgga ctcctaccgc taccccagga caggcagcaa gaaccccaag
960

attgccctga agctggctga gctccagacg gaccatcagg gcaaaatcgt gtcaagctgc
1020

gagaaggaac tggtacagcc attcagctcc cttttcccca aagtggagta catcgcccgg
1080

gctggctgga cacgggacgg caaatatgcc tgggccatgt tcctggaccg tccccagcaa
1140

cggcttcagc ttgtcctcct gccccctgct ctcttcatcc cggccgttga gagtgaggcc
1200

cagcggcagg cagctgccag agccgtcccc aagaatgtgc agccctttgt catctatgaa
1260

gaagtcacca atgtctggat caacgtccac gacatcttcc acccgtttcc tcaggctgag
1320

ggccagcagg acttttgttt ccttcgtgcc aacgaatgca agactggctt ctgccacctg
1380

tacagggtca cagtggaact taaaaccaag gactatgact ggacggaacc cctcagccct
1440

acagaaggtg agtttaagtg ccccatcaag gaggaggtcg ccctgaccag tggcgagtgg
1500

gaggtcttgt cgaggcatgg ctccaagatc tgggtcaacg agcagacgaa gctggtgtac
1560

tttcaaggta caaaggacac accgctggaa catcacctct atgtggtcag ctacgagtca
1620

gcaggcgaga tcgtgcggct caccacgctc ggcttctccc acagctgctc catgagccag
1680

agcttcgaca tgttcgtgag tcactacagc agtgtgagca cgccaccctg tgtacatgtg
1740

tacaagctga gcggccccga tgatgaccca ctgcacaagc aaccacgctt ctgggccagc
1800

atgatggagg cagccaattg ccccccagac tatgtgcccc ctgagatctt ccacttccac
1860

acccgtgcag acgtgcagct ctacggcatg atctacaagc cacacaccct gcaacctggg

1920

aggaagcacc ccactgtgct ctttgtctat gggggcccac aggtgcagtt ggtgaacaac
1980

tcctttaagg gcatcaaata cctgcggcta aatacactgg catccttggg ctatgctgtg
2040

gtggtgatcg atggtcgggg ctcctgtcag cggggcctgc acttcgaggg ggccctgaaa
2100

aatcaaatgg gccaggtgga gattgaggac caggtggaag gcttgcagta cgtggctgag
2160

aagtatggct tcattgactt gagccgagtc gccatccatg gctggtccta cggcggcttc
2220

ctctcactca tggggctcat ccacaagcca caagtgttca aggtagccat tgcgggcgct
2280

cctgtcactg tgtggatggc ctatgacaca gggtacacgg aacgatacat ggatgtcccc
2340

gaaaataacc agcaaggcta tgaggcaggg tctgtagccc tgcatgtgga gaagctgccc
2400

aatgagccta accgcctgct tatcctccac ggcttcctgg acgagaacgt tcacttcttc
2460

cacacaaatt tcctggtgtc ccagctgatc cgagcaggaa agccatacca gcttcagatc
2520

tacccaaacg agagacatag catccgctgc cgcgagtccg gagagcatta cgaggtgacg
2580

ctgctgcact ttctgcagga acacctgtga cctcagtccc gactcctgac gccaccgctg
2640

ctcttcttgc gtttttgtaa tcttttcatt tttgaagctt ccaatttgct tgctgctgct
2700

gctgcctggg ggccaggaca gaggtagtgg cggcccccat gccgccctcc ttgagctggt
2760

gaggagaagt cgccattgag cacacaacct ccaccagact gccatggccc cgaacctgca
2820

attccatcct agcgcagaag catgtgcctg ccacctgctg cccctgcaga gtcatgtgtg
2880

tttgtggtgg gcattttaaa taattattta aaagacagga agtaagcggt accgagcaat
2940

gaaactgaag gtacagcact gggcgtctgg ggaccccacg ctctcccaac gcccagacta
3000

tgtggagctg ccaagcccct gtctgggcac ctctgccctg cctgtctgct gcccggatcc
3060

tcctcactta gcacctaggg gtgtcagggt cgggagtagg acctgtcctg acctcagggt
3120

tatatatagc ccttccccac tccctcctac gagagttctg gcataaagaa gtaaaaaaaa
3180

aaaaaaaaaa aacaaacaaa aaaaccaaac cacctctaca tattatggaa agaaaatatt
3240

tttgtcaatt cttattcttt tataattatg tggtatgtag actcatt
3287

<210> 4
<211> 869
<212> PRT
<213> Mus musculus

<400> 4

Pro Ser Gln Glu Pro Gln Arg Met Cys Ser Gly Val Ser Pro Val Glu
1 5 10 15

Gln Val Ala Ala Gly Asp Met Asp Asp Thr Ala Ala Arg Phe Cys Val
20 25 30

Gln Lys His Ser Trp Asp Gly Leu Arg Ser Ile Ile His Gly Ser Arg
35 40 45

Lys Ser Ser Gly Leu Ile Val Ser Lys Ala Pro His Asp Phe Gln Phe
50 55 60

Val Gln Lys Pro Asp Glu Ser Gly Pro His Ser His Arg Leu Tyr Tyr
65 70 75 80

Leu Gly Met Pro Tyr Gly Ser Arg Glu Asn Ser Leu Leu Tyr Ser Glu
85 90 95

Ile Pro Lys Lys Val Arg Lys Glu Ala Leu Leu Leu Leu Ser Trp Lys

100 105 110

Gln Met Leu Asp His Phe Gln Ala Thr Pro His His Gly Val Tyr Ser
115 120 125

Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg Leu Gly Val Phe Gly
130 135 140

Ile Thr Ser Tyr Asp Phe His Ser Glu Ser Gly Leu Phe Leu Phe Gln
145 150 155 160

Ala Ser Asn Ser Leu Phe His Cys Arg Asp Gly Gly Lys Asn Gly Phe
165 170 175

Met Val Ser Pro Met Lys Pro Leu Glu Ile Lys Thr Gln Cys Ser Gly
180 185 190

Pro Arg Met Asp Pro Lys Ile Cys Pro Ala Asp Pro Ala Phe Phe Ser
195 200 205

Phe Ile Asn Asn Ser Asp Leu Trp Val Ala Asn Ile Glu Thr Gly Glu
210 215 220

Glu Arg Arg Leu Thr Phe Cys His Gln Gly Ser Ala Gly Val Leu Asp
225 230 235 240

Asn Pro Lys Ser Ala Gly Val Ala Thr Phe Val Ile Gln Glu Glu Phe
245 250 255

Asp Arg Phe Thr Gly Cys Trp Trp Cys Pro Thr Ala Ser Trp Glu Gly
260 265 270

Ser Glu Gly Leu Lys Thr Leu Arg Ile Leu Tyr Glu Glu Val Asp Glu
275 280 285

Ser Glu Val Glu Val Ile His Val Pro Ser Pro Ala Leu Glu Glu Arg
290 295 300

Lys Thr Asp Ser Tyr Arg Tyr Pro Arg Thr Gly Ser Lys Asn Pro Lys

305 310 315 320

Ile Ala Leu Lys Leu Ala Glu Leu Gln Thr Asp His Gln Gly Lys Ile
325 330 335

Val Ser Ser Cys Glu Lys Glu Leu Val Gln Pro Phe Ser Ser Leu Phe
340 345 350

Pro Lys Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr Arg Asp Gly Lys
355 360 365

Tyr Ala Trp Ala Met Phe Leu Asp Arg Pro Gln Gln Arg Leu Gln Leu
370 375 380

Val Leu Leu Pro Pro Ala Leu Phe Ile Pro Ala Val Glu Ser Glu Ala
385 390 395 400

Gln Arg Gln Ala Ala Ala Arg Ala Val Pro Lys Asn Val Gln Pro Phe
405 410 415

Val Ile Tyr Glu Glu Val Thr Asn Val Trp Ile Asn Val His Asp Ile
420 425 430

Phe His Pro Phe Pro Gln Ala Glu Gly Gln Gln Asp Phe Cys Phe Leu
435 440 445

Arg Ala Asn Glu Cys Lys Thr Gly Phe Cys His Leu Tyr Arg Val Thr
450 455 460

Val Glu Leu Lys Thr Lys Asp Tyr Asp Trp Thr Glu Pro Leu Ser Pro
465 470 475 480

Thr Glu Gly Glu Phe Lys Cys Pro Ile Lys Glu Glu Val Ala Leu Thr
485 490 495

Ser Gly Glu Trp Glu Val Leu Ser Arg His Gly Ser Lys Ile Trp Val
500 505 510

Asn Glu Gln Thr Lys Leu Val Tyr Phe Gln Gly Thr Lys Asp Thr Pro

515 520 525

Leu Glu His His Leu Tyr Val Val Ser Tyr Glu Ser Ala Gly Glu Ile
530 535 540

Val Arg Leu Thr Thr Leu Gly Phe Ser His Ser Cys Ser Met Ser Gln
545 550 555 560

Ser Phe Asp Met Phe Val Ser His Tyr Ser Ser Val Ser Thr Pro Pro
565 570 575

Cys Val His Val Tyr Lys Leu Ser Gly Pro Asp Asp Asp Pro Leu His
580 585 590

Lys Gln Pro Arg Phe Trp Ala Ser Met Met Glu Ala Ala Asn Cys Pro
595 600 605

Pro Asp Tyr Val Pro Pro Glu Ile Phe His Phe His Thr Arg Ala Asp
610 615 620

Val Gln Leu Tyr Gly Met Ile Tyr Lys Pro His Thr Leu Gln Pro Gly
625 630 635 640

Arg Lys His Pro Thr Val Leu Phe Val Tyr Gly Gly Pro Gln Val Gln
645 650 655

Leu Val Asn Asn Ser Phe Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr
660 665 670

Leu Ala Ser Leu Gly Tyr Ala Val Val Val Ile Asp Gly Arg Gly Ser
675 680 685

Cys Gln Arg Gly Leu His Phe Glu Gly Ala Leu Lys Asn Gln Met Gly
690 695 700

Gln Val Glu Ile Glu Asp Gln Val Glu Gly Leu Gln Tyr Val Ala Glu
705 710 715 720

Lys Tyr Gly Phe Ile Asp Leu Ser Arg Val Ala Ile His Gly Trp Ser

725 730 735

Tyr Gly Gly Phe Leu Ser Leu Met Gly Leu Ile His Lys Pro Gln Val
740 745 750

Phe Lys Val Ala Ile Ala Gly Ala Pro Val Thr Val Trp Met Ala Tyr
755 760 765

Asp Thr Gly Tyr Thr Glu Arg Tyr Met Asp Val Pro Glu Asn Asn Gln
770 775 780

Gln Gly Tyr Glu Ala Gly Ser Val Ala Leu His Val Glu Lys Leu Pro
785 790 795 800

Asn Glu Pro Asn Arg Leu Leu Ile Leu His Gly Phe Leu Asp Glu Asn
805 810 815

Val His Phe Phe His Thr Asn Phe Leu Val Ser Gln Leu Ile Arg Ala
820 825 830

Gly Lys Pro Tyr Gln Leu Gln Ile Tyr Pro Asn Glu Arg His Ser Ile
835 840 845

Arg Cys Arg Glu Ser Gly Glu His Tyr Glu Val Thr Leu Leu His Phe
850 855 860

Leu Gln Glu His Leu
865

<210> 5
<211> 3120
<212> DNA
<213> Homo sapiens

<400> 5
aagtgctaaa gcctccgagg ccaaggccgc tgctactgcc gccgctgctt cttagtgccg
60

cgttcgccgc ctgggttgtc accggcgccg ccgccgagga agccactgca accaggaccg
120

gagtggaggc ggcgcagcat gaagcggcgc aggcccgctc catagcgcac gtcgggacgg

180

tccgggcggg gccgggggga aggaaaatgc aacatggcag cagcaatgga aacagaacag
240

ctgggtgttg agatatttga aactgcggac tgtgaggaga atattgaatc acaggatcgg
300

cctaaattgg agccttttta tgttgagcgg tattcctgga gtcagcttaa aaagctgctt
360

gccgatacca gaaaatatca tggctacatg atggctaagg caccacatga tttcatgttt
420

gtgaagagga atgatccaga tggacctcat tcagacagaa tctattacct tgccatgtct
480

ggtgagaaca gagaaaatac actgttttat tctgaaattc ccaaaactat caatagagca
540

gcagtcttaa tgctctcttg gaagcctctt ttggatcttt ttcaggcaac actggactat
600

ggaatgtatt ctcgagaaga agaactatta agagaaagaa aacgcattgg aacagtcgga
660

attgcttctt acgattatca ccaaggaagt ggaacatttc tgtttcaagc cggtagtgga
720

atttatcacg taaaagatgg agggccacaa ggatttacgc aacaaccttt aaggcccaat
780

ctagtggaaa ctagttgtcc caacatacgg atggatccaa aattatgccc cgctgatcca
840

gactggattg cttttataca tagcaacgat atttggatat ctaacatcgt aaccagagaa
900

gaaaggagac tcacttatgt gcacaatgag ctagccaaca tggaagaaga tgccagatca
960

gctggagtcg ctacctttgt tctccaagaa gaatttgata gatattctgg ctattggtgg
1020

tgtccaaaag ctgaaacaac tcccagtggt ggtaaaattc ttagaattct atatgaagaa
1080

aatgatgaat ctgaggtgga aattattcat gttacatccc ctatgttgga aacaaggagg
1140

gcagattcat tccgttatcc taaaacaggt acagcaaatc ctaaagtcac ttttaagatg
1200

tcagaaataa tgattgatgc tgaaggaagg atcatagatg tcatagataa ggaactaatt
1260

caacctttg agattctatt tgaaggagtt gaatatattg ccagagctgg atggactcct
1320

gagggaaaat atgcttggtc catcctacta gatcgctccc agactcgcct acagatagtg
1380

ttgatctcac ctgaattatt tatcccagta gaagatgatg ttatggaaag gcagagactc
1440

attgagtcag tgcctgattc tgtgacgcca ctaattatct atgaagaaac aacagacatc
1500

tggataaata tccatgacat ctttcatgtt tttccccaaa gtcacgaaga ggaaattgag
1560

tttatttttg cctctgaatg caaaacaggt ttccgtcatt tatacaaaat tacatctatt
1620

ttaaaggaaa gcaaatataa acgatccagt ggtgggctgc ctgctccaag tgatttcaag
1680

tgtcctatca aagaggagat agcaattacc agtggtgaat gggaagttct tggccggcat
1740

ggatctaata tccaagttga tgaagtcaga aggctggtat attttgaagg caccaaagac
1800

tccccctttag agcatcacct gtacgtagtc agttacgtaa atcctggaga ggtgacaagg
1860

ctgactgacc gtggctactc acattcttgc tgcatcagtc agcactgtga cttctttata
1920

agtaagtata gtaaccagaa gaatccacac tgtgtgtccc tttacaagct atcaagtcct
1980

gaagatgacc caacttgcaa aacaaaggaa ttttgggcca ccattttgga ttcagcaggt
2040

cctcttcctg actatactcc tccagaaatt ttctcttttg aaagtactac tggatttaca
2100

ttgtatggga tgctctacaa gcctcatgat ctacagcctg gaaagaaata tcctactgtg
2160

ctgttcatat atggtggtcc tcaggtgcag ttggtgaata atcggtttaa aggagtcaag
2220

tatttccgct tgaataccct agcctctcta ggttatgtgg ttgtagtgat agacaacagg
2280

ggatcctgtc accgagggct taaatttgaa ggcgccttta aatataaaat gggtcaaata
2340

gaaattgacg atcaggtgga aggactccaa tatctagctt ctcgatatga tttcattgac
2400

ttagatcgtg tgggcatcca cggctggtcc tatggaggat acctctccct gatggcatta
2460

atgcagaggt cagatatctt cagggttgct attgctgggg ccccagtcac tctgtggatc
2520

ttctatgata caggatacac ggaacgttat atgggtcacc ctgaccagaa tgaacagggc
2580

tattacttag gatctgtggc catgcaagca gaaaagttcc cctctgaacc aaatcgttta
2640

ctgctcttac atggtttcct ggatgagaat gtccattttg cacataccag tatattactg
2700

agttttttag tgagggctgg aaagccatat gatttacaga tctatcctca ggagagacac
2760

agcataagag ttcctgaatc gggagaacat tatgaactgc atcttttgca ctaccttcaa
2820

gaaaaccttg gatcacgtat tgctgctcta aaagtgatat aattttgacc tgtgtagaac
2880

tctctggtat acactggcta tttaaccaaa tgaggaggtt taatcaacag aaaacacaga
2940

attgatcatc acattttgat acctgccatg taacatctac tcctgaaaat aaatgtggtg
3000

ccatgcaggg gtctacggtt tgtggtagta atctaatacc ttaaccccac atgctcaaaa
3060

tcaaatgata catattcctg agagacccag caataccata agaattacta aaaaaaaaaa
3120

<210> 6
<211> 882
<212> PRT
<213> Homo sapiens

<400> 6

```
Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1               5                  10                  15

Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
            20                  25                  30

Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
        35                  40                  45

Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
    50                  55                  60

His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65                  70                  75                  80

Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
                85                  90                  95

Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu
            100                 105                 110

Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp
        115                 120                 125

Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg
    130                 135                 140

Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly
145                 150                 155                 160

Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly
                165                 170                 175

Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu
            180                 185                 190

Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp
        195                 200                 205
```

```
Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn
    210                 215                 220

Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu
225                 230                 235                 240

Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val
                245                 250                 255

Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys
            260                 265                 270

Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu
        275                 280                 285

Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met
    290                 295                 300

Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr
305                 310                 315                 320

Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala
                325                 330                 335

Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe
            340                 345                 350

Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr
        355                 360                 365

Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr
    370                 375                 380

Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu
385                 390                 395                 400

Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser
                405                 410                 415
```

Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn
420 425 430

Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile
435 440 445

Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr
450 455 460

Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly
465 470 475 480

Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile
485 490 495

Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn
500 505 510

Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys
515 520 525

Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro
530 535 540

Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys
545 550 555 560

Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys
565 570 575

Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp
580 585 590

Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala
595 600 605

Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser
610 615 620

Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu
625 630 635 640

Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Pro
645 650 655

Gln Val Gln Leu Val Asn Asn Arg Phe Lys Gly Val Lys Tyr Phe Arg
660 665 670

Leu Asn Thr Leu Ala Ser Leu Gly Tyr Val Val Val Val Ile Asp Asn
675 680 685

Arg Gly Ser Cys His Arg Gly Leu Lys Phe Glu Gly Ala Phe Lys Tyr
690 695 700

Lys Met Gly Gln Ile Glu Ile Asp Asp Gln Val Glu Gly Leu Gln Tyr
705 710 715 720

Leu Ala Ser Arg Tyr Asp Phe Ile Asp Leu Asp Arg Val Gly Ile His
725 730 735

Gly Trp Ser Tyr Gly Gly Tyr Leu Ser Leu Met Ala Leu Met Gln Arg
740 745 750

Ser Asp Ile Phe Arg Val Ala Ile Ala Gly Ala Pro Val Thr Leu Trp
755 760 765

Ile Phe Tyr Asp Thr Gly Tyr Thr Glu Arg Tyr Met Gly His Pro Asp
770 775 780

Gln Asn Glu Gln Gly Tyr Tyr Leu Gly Ser Val Ala Met Gln Ala Glu
785 790 795 800

Lys Phe Pro Ser Glu Pro Asn Arg Leu Leu Leu Leu His Gly Phe Leu
805 810 815

Asp Glu Asn Val His Phe Ala His Thr Ser Ile Leu Leu Ser Phe Leu
820 825 830

Val Arg Ala Gly Lys Pro Tyr Asp Leu Gln Ile Tyr Pro Gln Glu Arg
835 840 845

His Ser Ile Arg Val Pro Glu Ser Gly Glu His Tyr Glu Leu His Leu
850 855 860

Leu His Tyr Leu Gln Glu Asn Leu Gly Ser Arg Ile Ala Ala Leu Lys
865 870 875 880

Val Ile

<210> 7
<211> 830
<212> PRT
<213> Homo sapiens

<400> 7

Leu Arg Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val
1 5 10 15

Asn Lys Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser
20 25 30

Gly Pro His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser
35 40 45

Arg Glu Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys
50 55 60

Glu Ala Leu Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln
65 70 75 80

Ala Thr Pro His His Gly Val Tyr Ser Arg Glu Glu Glu Leu Leu Arg
85 90 95

Glu Arg Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His
100 105 110

```
Ser Glu Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His
        115                 120                 125

Cys Arg Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro
    130                 135                 140

Leu Glu Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile
145                 150                 155                 160

Cys Pro Ala Asp Pro Ala Phe Phe Ser Phe Asn Asn Asn Ser Asp Leu
                165                 170                 175

Trp Val Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys
            180                 185                 190

His Gln Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val
        195                 200                 205

Ala Thr Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp
    210                 215                 220

Trp Cys Pro Thr Ala Ser Trp Glu Gly Ser Gln Gly Leu Lys Thr Leu
225                 230                 235                 240

Arg Ile Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His
                245                 250                 255

Val Pro Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr
            260                 265                 270

Pro Arg Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu
        275                 280                 285

Phe Gln Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu
    290                 295                 300

Leu Val Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala
305                 310                 315                 320
```

Arg Ala Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu
325 330 335

Asp Arg Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu
340 345 350

Phe Ile Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg
355 360 365

Ala Val Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr
370 375 380

Asn Val Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser
385 390 395 400

Glu Gly Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr
405 410 415

Gly Phe Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly
420 425 430

Tyr Asp Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys
435 440 445

Pro Ile Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu
450 455 460

Ala Arg His Gly Ser Lys Ile Trp Val Asn Glu Glu Thr Lys Leu Val
465 470 475 480

Tyr Phe Gln Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr Val
485 490 495

Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro Gly
500 505 510

Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val Ser
515 520 525

His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys Leu
530 535 540

Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp Ala
545 550 555 560

Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro Glu
565 570 575

Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met Ile
580 585 590

Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val Leu
595 600 605

Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe Lys
610 615 620

Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr Ala
625 630 635 640

Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg Phe
645 650 655

Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp Gln
660 665 670

Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp Leu
675 680 685

Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser Leu
690 695 700

Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala Gly
705 710 715 720

Ala Pro Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu Arg
725 730 735

Tyr Met Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly Ser
740 745 750

Val Ala Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu Leu
755 760 765

Ile Leu His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr Asn
770 775 780

Phe Leu Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu Gln
785 790 795 800

Ile Tyr Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly Glu
805 810 815

His Tyr Glu Val Thr Leu Leu His Phe Leu Gln Glu Tyr Leu
820 825 830

<210> 8
<211> 2495
<212> DNA
<213> Homo sapiens

<400> 8
ctccggagca tcatccacgg cagccgcaag tactcgggcc tcattgtcaa caaggcgccc
60

cacgacttcc agtttgtgca gaagacggat gagtctgggc cccactccca ccgcctctac
120

tacctgggaa tgccatatgg cagccgggag aactccctcc tctactctga gattcccaag
180

aaggtccgga aagaggctct gctgctcctg tcctggaagc agatgctgga tcatttccag
240

gccacgcccc accatggggt ctactctcgg gaggaggagc tgctgaggga gcggaaacgc
300

ctgggggtct tcggcatcac ctcctacgac ttccacagcg agagtggcct cttcctcttc
360

caggccagca acagcctctt ccactgccgc gacggcggca agaacggctt catggtgtcc
420

cctatgaaac cgctggaaat caagacccag tgctcagggc cccggatgga ccccaaaatc

480

tgccctgccg accctgcctt cttctccttc aacaataaca gcgacctgtg ggtggccaac
540

atcgagacag gcgaggagcg gcggctgacc ttctgccacc aaggtttatc caatgtcctg
600

gatgacccca agtctgcggg tgtggccacc ttcgtcatac aggaagagtt cgaccgcttc
660

actgggtact ggtggtgccc cacagcctcc tgggaaggtt cagagggcct caagacgctg
720

cgaatcctgt atgaggaagt cgatgagtcc gaggtggagg tcattcacgt cccctctcct
780

gcgctagaag aaaggaagac ggactcgtat cggtacccca ggacaggcag caagaatccc
840

aagattgcct tgaaactggc tgagttccag actgacagcc agggcaagat cgtctcgacc
900

caggagaagg agctggtgca gcccttcagc tcgctgttcc cgaaggtgga gtacatcgcc
960

agggccgggt ggacccggga tggcaaatac gcctgggcca tgttcctgga ccggccccag
1020

cagtggctcc agctcgtcct cctcccccg gccctgttca tcccgagcac agagaatgag
1080

gagcagcggc tagcctctgc cagagctgtc cccaggaatg tccagccgta tgtggtgtac
1140

gaggaggtca ccaacgtctg gatcaatgtt catgacatct tctatccctt cccccaatca
1200

gagggagagg acgagctctg ctttctccgc gccaatgaat gcaagaccgg cttctgccat
1260

ttgtacaaag tcaccgccgt tttaaaatcc cagggctacg attggagtga gcccttcagc
1320

cccggggaag atgaatttaa gtgccccatt aaggaagaga ttgctctgac cagcggtgaa
1380

tgggaggttt tggcgaggca cggctccaag atctgggtca atgaggagac caagctggtg
1440

tacttccagg gcaccaagga cacgccgctg gagcaccacc tctacgtggt cagctatgag
1500

gcggccggcg agatcgtacg cctcaccacg cccggcttct cccatagctg ctccatgagc
1560

cagaacttcg acatgttcgt cagccactac agcagcgtga gcacgccgcc ctgcgtgcac
1620

gtctacaagc tgagcggccc cgacgacgac cccctgcaca agcagccccg cttctgggct
1680

agcatgatgg aggcagccag ctgcccccg gattatgttc ctccagagat cttccatttc
1740

cacacgcgct cggatgtgcg gctctacggc atgatctaca agccccacgc cttgcagcca
1800

gggaagaagc accccaccgt cctctttgta tatggaggcc cccaggtgca gctggtgaat
1860

aactccttca aaggcatcaa gtacttgcgg ctcaacacac tggcctccct gggctacgcc
1920

gtggttgtga ttgacggcag gggctcctgt cagcgagggc ttcggttcga aggggccctg
1980

aaaaaccaaa tgggccaggt ggagatcgag gaccaggtgg agggcctgca gttcgtggcc
2040

gagaagtatg gcttcatcga cctgagccga gttgccatcc atggctggtc ctacgggggc
2100

ttcctctcgc tcatggggct aatccacaag ccccaggtgt tcaaggtggc catcgcgggt
2160

gccccggtca ccgtctggat ggcctacgac acagggtaca ctgagcgcta catggacgtc
2220

cctgagaaca accagcacgg ctatgaggcg ggttccgtgg ccctgcacgt ggagaagctg
2280

cccaatgagc ccaaccgctt gcttatcctc cacggcttcc tggacgaaaa cgtgcacttt
2340

ttccacacaa acttcctcgt ctcccaactg atccgagcag ggaaacctta ccagctccag
2400

atctacccca acgagagaca cagtattcgc tgccccgagt cgggcgagca ctatgaagtc
2460

acgttactgc actttctaca ggaatacctc tgagc
2495

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU01/01388

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. [7]: C12N 9/64, 5/10, 5/12; A61K 38/43; C07K 16/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

ANGIS sequence search: sequence ID No 2, 4 and 7;
STN: File CA sequences in claim 1 part (b)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Eur. J. Biochem, Volume 267, No.20, issued Oct 2000, C.A.Abbott et al, "Cloning , expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8", pages 6140-6150. See whole document but in particular abstract and sequence listings.	1-23
P,X	WO 01/19866 A1 (THE UNIVERSITY OF SYDNEY) 22 March 2001 Whole document.	1-23
P,X	GenPept accession Number AAH00970 mRNA, partial cds. Submitted 16 Nov 2000.	24, 25

☐ Further documents are listed in the continuation of Box C ☒ See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
6 December 2001	13 DEC 2001
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized officer K. LEVER Telephone No : (02) 6283 2254

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU01/01388

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Member
WO 01/19866	AU 73946/00

END OF ANNEX